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Abstract 
 
 
The immaturity of the neonatal immune system places infants at an increased risk of 
infections and also affects the effective induction of protective immune responses by 
vaccines. In utero sensitisation to infectious pathogens results in immune activation 
and can establish immunological memory and may influence the immune response to 
unrelated antigens. In this study, we investigated in early life (birth to 6-10 weeks) the 
development of interferon-gamma (IFN-γ) responses in uninfected infants born to 
HIV-1 infected mothers (exposed uninfected (EU) infants). 
 
Whole blood cell cultures stimulated with phytohaemagglutinin (PHA) or 
Mycobacterium bovis bacillus Calmette-Guérin (BCG) showed that EU infants have a 
greater ability to produce IFN-γ in response to PHA and BCG at birth compared to 
control infants (born to HIV-1 uninfected mothers). However, by six weeks of age 
control infants produced significantly more IFN-γ in response to PHA only. These 
results suggest that responses amongst EU infants establish and mature earlier than 
in control infants. In fact, over time a greater number of EU infants have a reduced 
ability or an inability to respond to stimuli such as PHA or BCG compared to control 
infants (when comparing responses at six weeks of age to responses of the matched 
birth samples).  
 
Full blood counts (FBC) counts were carried out using an automated AcT 5 diff 
haematology analyser which measures proportions and absolute counts of the five 
groups of white blood cells, namely, lymphocytes, monocytes, neutrophils, 
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eosinophils and basophils. Importantly, there were no significant differences in the 
absolute lymphocyte counts of control infants and EU infants either at birth or at six 
weeks which could account for the IFN-γ production differences noted between these 
infant groups, although the EU infants did exhibit a trend of higher absolute 
lymphocyte counts at six weeks than control infants. Age-dependent maturational 
changes in cell counts were observed in both control and EU infant groups, with 
neutrophils predominating at birth and lymphocytes predominating by six weeks, 
indicative of immune development with age in both infant groups. Short-course 
antiretroviral exposure increased basophil counts of infants at birth but did not affect 
counts by six weeks.  
 
Flow Cytometry studies using an Intracellular Cytokine (ICC) assay were conducted 
to establish which mononuclear cell types are predominantly responsible for 
producing IFN-γ in infants. ICC assays done on whole blood revealed that natural 
killer cells (NK) were predominantly responsible for the IFN-γ produced by 10 week 
old EU infants, and also at birth (control and EU infants). At birth whole blood cultures 
of 48% of EU infants already showed BCG-induced IFN-γ responses (prior to BCG 
vaccination); this could be explained by a non-specific response (NK cells) to the 
antigen but could also involve T cell responses (CD4+ and/or CD8+ T cells) as 
supported by ICC data obtained from control and EU newborn infants. The infant 
immune system was clearly unique from that of their mothers. In particular, mothers’ 
demonstrated significant changes in blood counts from labour to six weeks 
postpartum indicative that immuno-modulation plays an essential role in a successful 
pregnancy. The single dose of nevirapine (sdNVP) taken by the mother at the onset 
of labour did not influence maternal blood counts significantly and maternal CD4+ and 
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CD8+ T cells, and NK cells produced significantly more IFN-γ than the CD14+ 
monocytes and CD19+ B cells, with CD8+ T cells producing the most.  
 
Our results have shown that EU infants are distinct from control infants with respect to 
immunological responses as measured by IFN-γ production, and that maturational 
differences do exist between control and HIV-1 exposed infants. While the clinical 
importance of these results remains undetermined it is important to establish whether 
such immunological changes may result in altered susceptibility to infectious diseases 
in this already vulnerable population, and how this may impact on the induction of 
protective immune responses by vaccines. It remains important to identify neonatal 
immune system deficiencies and understand the consequences of exposure to 
maternal HIV-1 (in the absence of acquiring HIV-1 infection), the understanding of 
which could contribute to the development of more effective vaccines to HIV-1 and 
other infectious diseases. 
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CHAPTER 1  
 
 
Introduction 
 
1.1 The immune system - innate and adaptive immunity 
 
A normal immune system is designed to keep potential environmental pathogenic 
microbes from gaining entrance and causing disease. This system comprises of two 
arms namely, the non-specific innate and the antigen-specific adaptive immune 
systems (Delves et al., 2000). Both are further divided into humoral and cellular 
components. Innate immunity is the body’s first line of defence against all invaders. 
The barriers employed are physical, chemical and microbiological in nature and 
encompass elements of the immune system (neutrophils, monocytes, macrophages, 
complement, cytokines and acute phase proteins) which provide immediate host 
defence (Delves et al., 2000). This system is not able to detect intracellular 
organisms, notably viruses, mycobacteria, some fungi, protozoa or other facultative 
intracellular pathogens. The response is rapid, non-specific and often poorly targeted, 
and can lead to indiscriminate tissue damage (Parkin et al., 2001). These innate 
immune mechanisms hinder the entrance and spread of disease but can rarely 
prevent disease completely. If an invader gets past the first line of defence, 
specifically adapted defences come into play in the form of the adaptive arm of the 
response. Superficially the system functions quite simply. If the organism is capable 
of replicating outside of cells, the humoral immune response, mediated by antibody 
molecules, is of primary importance. By comparison if the microbe can live and 
replicate inside cells, as most viruses do, then they can evade the antibodies, and cell 
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mediated immunity (CMI) comes into play (http://encarta.msn.com/encyclopedia 
761575681 /Immune_System.html). During humoral immune responses, antibodies 
which can adhere to and destroy antigens, appear in the blood and other bodily fluids. 
Humoral responses can also prevent viruses from entering cells. During CMI 
responses, cells that can destroy other cells become active. Their destructive activity 
is limited to cells that are either infected with, or producing a specific antigen. CMI 
responses may also destroy cells making mutated forms of normal molecules, as in 
some cancers (http://encarta.msn.com/text 761575681 /Immune_System.html). The 
adaptive response is precise but takes several days or weeks to develop. The 
adaptive response has memory, so that subsequent exposure leads to a more 
vigorous and rapid response. Ideally the adaptive response eliminates the infectious 
agent and provides the host with a state of protective immunity against re-infection 
with the same pathogen (Janeway et al., 2001).  
 
1.1.1 The induced innate response 
 
Innate immunity employs a variety of induced effector mechanisms to either clear an 
infection rapidly or to stave off infection while the adaptive response develops. These 
effector mechanisms are all regulated by the ligand binding abilities of pattern 
recognition molecules that are able to discriminate between non-infected self and 
infectious non-self ligands. Thus the phagocytes ability to discriminate between self 
and pathogen, controls its release of pro-inflammatory chemokines and cytokines that 
act together to recruit more phagocytic  cells, especially neutrophils, (which can also 
recognize pathogens), to the site of infection (Aderem et al., 1999; DeVries et al., 
1999; Janeway et al., 2001). Furthermore, cytokines released by the inflammatory 
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process, induce fever, the production of acute phase response proteins including the 
pathogen-binding mannan binding lectin and the C-reactive proteins, and the 
mobilization of antigen-presenting cells that induce the adaptive immune response. 
These cytokines include interleukin (IL)-6, IL-1 (beta), tumour necrosis factor (alpha) 
(TNF-α), interferon gamma (IFN-γ), transforming growth factor (beta) (TGF-β) and 
possibly IL-8 (Gabay et al., 1999;). Viral pathogens are recognised by the cells in 
which they replicate, leading to the production of interferons that serve to inhibit viral 
replication. They activate natural killer (NK) cells, which in turn can distinguish 
infected from non-infected cells. During the innate response the cytokines produced 
play a role in determining whether the response is T cell-mediated or predominantly 
humoral and subsequently shape and stimulate the development of the adaptive 
immune response (Bendelac et al., 1997; Hsieh et al., 1993; Moser et al., 2000; 
Janeway et al., 2001). 
 
1.1.2 T cell-mediated immunity 
 
Dendritic cells, macrophages and B cells are often known as professional antigen-
presenting cells. Antigen presenting cells (APC) present antigens of the pathogen in 
the form of a short peptide in association with major histocompatibility (MHC) 
molecules to mature T cells (Wilson et al., 1992), that are constantly recirculating 
from the bloodstream through the lymphoid organs and scanning the environment for 
pathogens. T cell priming and the differentiation of armed effector T cells occur here, 
on the surface of the antigen-loaded dendritic cells, which result in the production of 
an expanded population of armed antigen-specific effector T cells (Nikolic-Zugic, 
1991). Effector T cells fall into three functional classes that detect peptide antigens 
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derived from the different types of pathogen (i) MHC class I molecules bearing viral 
peptides are recognized by cytotoxic T cells (CTLs) which then kill infected target 
cells (ii) MHC class II molecules bearing peptide antigens from pathogens multiplying 
in intracellular vesicles, which are recognised by T helper-type 1 (Th1) or T helper 
type 2 (Th2) cells and (iii) those derived from ingested extracellular bacteria and 
toxins, are carried to the cell surface by the MHC class II molecules and presented to 
CD4+ T cells (Cao et al., 1995; Wilson et al., 1992). These can differentiate into two 
types of effector T cells - Th1 and Th2 cells. Th1 cells activate the microbicidal 
properties of macrophages, and induce B cells to make IgG antibodies that are very 
effective at opsonizing extracellular pathogens for uptake by phagocytic cells. Th2 
cells initiate the humoral response by activating the naïve antigen-specific B cells to 
produce IgM antibodies. These Th2 cells can subsequently stimulate the production 
of different isotypes, including IgA and IgE, as well as neutralizing and/or weakly 
opsonizing subtypes of IgG (Romagnani, 2006; Elson et al., 2000). 
 
1.2 Development of cells of the immune system 
 
Haematopoietic stem cells (HSC) are found in the bone marrow of adults, which 
includes the femurs, hip, ribs, sternum and other bones. HSC are progenitor or early 
precursor cells which give rise to all the blood cell types that include both the myeloid 
lineage (monocytes and macrophages, neutrophils, basophils, eosinophils, 
erythrocytes, and dendritic cells) and lymphoid lineages (T cells, B cells and NK cells) 
(Abramson et al., 1977; Wu et al., 1967). Fig.1.1 schematically presents the 
development of the cells of the immune system. Common lymphoid progenitor cells 
that arise in the foetal liver and bone marrow give rise to both myeloid and lymphoid 
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cells including B and T lymphocytes (Abramson et al., 1977). There are also stem 
cells committed to differentiation only into T lymphocytes (Abramson et al., 1977). 
The thymus is the main site of T cell maturation whereas the B lymphocytes mature in 
the bone marrow. Precursor cells first colonise the thymus in the human at about the 
third week of gestation and continue to migrate into this organ throughout adult life, 
where they (thymocytes) undergo a series of differentiative events which includes 
gene rearrangement, phenotypic alteration and biochemical modification to yield the 
population of thymocytes that undergoes intrathymic selection (Wilson et al., 1992). 
Once they have completed their maturation, naïve T cells recirculate continually from 
the bloodstream from which they migrate to the peripheral lymphoid organs, namely 
the lymph nodes, the spleen and the mucosal lymphoid organs (Janeway, 2001). 
Lymphoid stem cells differentiate into three major populations of mature lymphocytes: 
T cells, B cells and NK cells. These lymphocyte subsets can be discriminated by 
surface phenotype. T cells are defined by their cell surface expression of the cell 
receptor, namely the T cell receptor (TCR), a transmembrane heterodimeric protein 
that binds processed antigen displayed by APC; B cells are phenotypically defined by 
their expression of the B cell receptor for antigen, membrane anchored 
immunoglobulin (Chaplin, 2003). NK cells are defined morphologically as large 
granular lymphocytes. They recognise their virus-infected or tumour cell targets 
through the use of a complex collection of activating and inhibitory cell surface 
receptors (Chaplin, 2003).  
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Fig. 1.1 Haematopoietic stem cells derived cell lineages. Pluripotent haematopoietic 
stem cells differentiate in bone marrow into lymphoid or myeloid stem cells. Lymphoid 
stem cells give rise to B cell, T cell and NK cell lineages. Myeloid stem cells give rise 
to a second level of lineage-specific colony forming unit (CFU) cells that go on to 
produce neutrophils, monocytes, eosinophils, basophils, mast cells, megakaryocytes, 
and erythrocytes. Monocytes differentiate further into macrophages in peripheral 
tissue compartments (Reproduced from Janeway et al., 2001) 
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1.2.1 Cellular components of the immune response 
 
1.2.1.1 Neutrophils 
 
Neutrophils are the most abundant type of white blood cells and form an integral part 
of the innate immune system. During the very early stages of infection, activated 
macrophages, endothelium and mast cells release cytokines. Two of these, 
granulocyte and granulocyte macrophage stimulating factors, stimulate division of 
myeloid precursors in the bone marrow, releasing millions of cells into the circulation 
and causing a characteristic neutrophil leukocytosis. Neutrophils normally flow freely 
in the blood. They undergo a process called chemotaxis that allows them to migrate 
towards sites of infection or inflammation (von Adrian et al., 2000; Parkin et al., 2001). 
Cell surface receptors are able to detect chemical gradients of molecules such as IL-
8, IFN-γ and complement 5a (C5a) which these cells use to direct the path of their 
migration (Parkin et al., 2001). Neutrophils are active phagocytes, capable of 
ingesting microorganisms or particles. They can only execute one phagocytic event, 
expending all glucose reserves in an extremely vigorous respiratory burst. The 
respiratory burst involves the activation of reduced nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase enzyme, which produces large quantities of superoxide 
and is sequentially reduced to singlet oxygen (Garred et al., 1995; Parkin et al., 
2001). Neutrophils also release an assortment of proteins in three types of granules: 
(i) specific granules - these help kill the ingested microbe by a variety of oxygen-
dependent mechanisms, (ii) azurophilic granules e.g. myeloperoxidase, (iii) tertiary 
granules, namely cathepsin and gelatinase. Ingestion and killing of organisms is 100-
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fold more effective if the particle is first opsonised with specific antibody or 
complement (Borregaard et al., 2007). 
 
1.2.1.2 Eosinophils, basophils and mast cells 
 
Eosinophils are not phagocytic. These cells are much rarer than neutrophils. In 
humans these cells comprise about 2-10% of peripheral leukocytes. Eosinophils are 
predominantly tissue cells and do not re-enter the circulation (Colley, 1973). They act 
by releasing components of their granules onto the surface of organisms. The cationic 
proteins and reactive oxygen metabolites released are cytotoxic to the organism. The 
main role of eosinophils is in protecting the host from parasitic infections. Such 
infections induce antigen-specific IgE production, the antibodies coating the 
organism. Eosinophils bind to the antibody using their low affinity receptors (FcR11) 
(Parkin et al., 2001). Eosinophils and basophils are more immediately concerned with 
the production of mediators that shape the inflammatory milieu, and are responsive to 
cytokines elaborated by the adaptive immune system. Mast cells and basophils play a 
central role in inflammatory and immediate allergic reactions. They are able to release 
potent inflammatory mediators, such as histamine, proteases, chemotactic factors 
and cytokines that act on the vasculature, smooth muscle, connective tissue, mucous 
glands and inflammatory cells. There are at least two types of mast cells based on 
enzymes they contain and tissue location. T mast cells (mucosal mast cells) contain 
only trypsin whereas connective tissue mast cells contain both trypsin and 
chymotrypsin (Parkin et al., 2001; Delves et al., 2000). 
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1.2.1.3 Dendritic cells 
 
Dendritic cells are derived from haematopoietic bone marrow progenitor cells. These 
progenitor cells initially transform into immature dendritic cells. Their main function is 
to process antigen material and present it on the surface to other cells of the immune 
system, thus functioning as APC (Banchereau et al., 1998). Dendritic cells are 
present in small quantities in tissues that are in contact with the external environment, 
mainly the skin (where they are often called langerhans cells) and the inner lining of 
the nose, lungs, stomach and intestines. They can also be found at an immature state 
in the blood. Once activated, they migrate to the lymphoid tissues where they interact 
with T cells and B cells to initiate and shape the adaptive immune response (Ingulli et 
al., 1997; Matsuno et al., 1996). At certain development stages they grow branched 
projections, the dentrites that give the cell its name. However, these do not have any 
special relation with neurons, which also possess similar appendages (Steinman et 
al., 1979). Immature dendritic cells constantly sample the surrounding environment 
for pathogens such as viruses and bacteria. This is done through pattern recognition 
receptors (PRRs) such as the toll-like receptors (TLRs) (Kabelitz et al., 2007). TLRs 
recognize specific chemical signatures found on subsets of pathogens. Once they 
have come into contact with such a pathogen, they become activated into mature 
dendritic cells. Immature dendritic cells phagocytose pathogens and degrade its 
proteins and upon maturation present those fragments at their cell surface using MHC 
molecules (Kabelitz et al., 2007). Simultaneously, they upregulate cell-surface 
receptors that act as co-receptors in T cell activation such as CD80, CD86, and CD40 
greatly enhancing their ability to activate T cells (Pasare et al., 2004). The dendritic 
cell is induced to travel through the blood stream to the spleen or through the 
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lymphatic system to a lymph node (Pasare et al., 2004). Here they act as APCs: they 
activate helper T cells and killer T cells as well as B cells by presenting them with 
antigens derived from the pathogen, alongside non-antigen specific costimulatory 
signals (Janeway et al., 1994; Knight et al., 1993). Every helper T cell is specific to 
one particular antigen. Only professional APCs (macrophages, B lymphocytes, and 
dendritic cells) are able to activate a helper T cell which has never encountered its 
antigen before. Dendritic cells are the most potent of all the antigen-presenting cells. 
Myeloid DC probably form monocytes, white blood cells which circulate in the body 
and, depending on the right signal, can turn into either dendritic cells or macrophages 
(Janeway et al., 1994). 
 
1.2.1.4 Natural killer cells 
 
NK cells originate from the common lymphoid progenitor cells, continue development 
in the bone marrow and circulate in the blood. They are larger than T and B 
lymphocytes and have distinctive cytoplasmic granules. Without the need for prior 
immunization or activation they are able to infiltrate the sites of early tumours or 
infectious agents in the body. They recognise their targets in one of two ways. First 
they bear Fc receptors that bind antibody coated targets leading to antibody-
dependent cellular cytotoxicity (ADCC). The second system relies on the killer 
activating receptors and killer inhibitory receptors of these cells. The killer activating 
receptors recognise a number of different molecules present on the surface of 
nucleated cells, whereas the killer inhibitory receptors recognise MHC class I 
molecules, which are usually present on all nucleated cells. NK cells are activated in 
response to interferons or macrophage-derived cytokines. When NK cells are 
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exposed to IFN-α, IFN-β or IL-12 the killing activity of these cells is increased (Parkin 
et al., 2001; Janeway et al., 2001).  
 
1.3 Cytokines 
 
Cytokines are small proteins that are produced by virtually all cells, usually in 
response to an activating stimulus and have a wide variety of functions. Cytokines 
send intracellular signals by binding to specific cell surface receptors. The term 
cytokine is a general name; other names include lymphokine (cytokines made by 
lymphocytes), chemokine (cytokines with chemotactic activities), and interleukins 
(cytokines made by one leukocyte and acting on other leukocytes). They can act in an 
autocrine manner, affecting the behaviour of the cell that releases the cytokine, or in a 
paracrine manner, affecting the behaviour of adjacent cells. Some cytokines can act 
in an endocrine manner, affecting the behaviour of distant cells 
(http://www2.gsu.edu/-biopjd/Lecture20F99.html). 
 
1.3.1 Interferons 
 
Interferons are a major class of cytokine that have a particular role in immunity. They 
are divided into type 1 interferons (α and β) which are the classical interferons 
induced in response to viral infections and type 2 interferons (γ or immune interferon). 
Type 1 interferons have potent antiviral activity as a primary function (Boehm et al., 
1997). Both α and β interferon bind to the same cellular receptor and protect 
uninfected cells by inducing the intracellular production of molecules that inhibit or 
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interfere with viral RNA and DNA production. They increase the expression of MHC 
class I molecules leading to enhanced recognition of virally infected cells by specific 
cytotoxic T lymphocytes. Type 1 interferons also have an antiproliferative function and 
have been used in combination with antiviral drugs to treat some viral infections 
(Belardelli, 1995; Durbin et al., 2000). 
 
1.3.1.1 Interferon-γ  
 
The antiviral effects of IFN-γ were first identified in PHA-activated lymphocyte 
supernatants (Wheelock, 1965). Since then a wealth of research has focused on this 
antiviral aspect (Revel et al, 1986; Staeheli, 1990; Kerr et al., 1992). It was initially 
thought that cells of the lymphoid system, namely, CD4+, CD8+, NK and γδ T cells 
were the only cells capable of producing IFN-γ however, macrophages and dendritic 
cells have also been shown to produce IFN-γ (Szabo et al., 2003). A number of 
cytokines (eg. IL-12, IL-18), microbial products (eg. LPS), and signalling pathways (eg 
CD40) are capable of inducing IFN-γ production from macrophages or dendritic cells. 
IL-12 and IL-18 together induce maximal IFN-γ from macrophages and dendritic cells, 
whereas IL-12 alone is capable of strongly inducing IFN-γ (Szabo et al., 2003). IFN-γ 
has a number of immunoregulatory functions in addition to its antiviral effects, acting 
directly on the immune system to activate macrophage and neutrophil intracellular 
killing, stimulate NK cell function, and enhance antigen presentation by increasing 
MHC class II expression on APC (Trienchieri, 1995; Young et al., 1995; Nathan et al., 
1983). A necessary step in the functioning of the IFN-γ is the interaction of IFN-γ with 
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receptors located on the surface of the cells, to subsequent activation of gene 
transcription. Over 200 genes are known to be regulated by IFN-γ (Boehm et al., 
1997). The primary method of IFN-γ signal transduction is via a Jak-Stat tyrosine 
kinase dependant pathway (Ellis et al., 2004). 
 
1.4 Immunity in the neonate 
 
Human neonates are highly susceptible to infections by bacteria, fungi, and viruses. 
Deficiencies of both innate and adaptive immunity contribute to the impaired neonatal 
host defence (Marodi, 2006). Many components of the immune system function less 
well in neonates compared with adults giving rise to a concept “of immunodeficiency 
or immaturity” (Schelonka et al., 1998). Table 1.1 lists some differences noted in 
infants when compared to adult immune systems. 
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Table 1.1 Features of infants’ immune systems that are characteristically 
different from adult immune systems [Reproduced and modified from Jaspan et 
al., (2006)]  
Neutrophils Higher number of circulating neutrophils, but decreased response to chemokines 
(Tan et al., 1995) 
DC and other APC In the presence of endogenous APC, human cord blood T cells proliferate 
poorly, and are poor producers of cytokines, including IL-12, IFN-γ, IL-4, GM-
CSF and IL-5 (Adkins, 1999). Immature neonatal DC have decreased antigen 
presenting ability (Salio et al., 2003)  
Helper T cell Th2 skewed response until ± 12 months (Hassan et al.,2000; Siegrest, 2001; 
Upham et al.,2002). Neonates and children produce less IL-2, IL-4, IL-6 and IL-
10 in response to mitogens (Chheda et al., 1996; Lewis et al., 1988; Lilac et al., 
1997). Neonatal CD4+ cells are less able to provide help for immunoglobulin 
synthesis (Splawski et al., 1991; Jelinek et al., 1986). 
Cytotoxic T cell Full maturation at 9 to 12 months (Chiba et al., 1989) 
IFN-γ Reach adult levels at 1-5 years (Chelimo et al., 2003). However certain 
immunogens can stimulate better IFN-γ responses eg BCG (Mahon, 2001) 
IgG Maternal IgG is present until 12-18 months. Infant IgG production increases 
sharply after the first few months, then gradually increases to adult levels at 2-7 
years. Relative nadir 3-6 months (Janeway et al., 1999). 
IgA Maternal IgA throughout breast feeding (Janeway et al., 1999). Infant serum IgA 
increases very slowly after birth; only 20% of adult levels by 12 months 
(Janeway et al., 1999). In the postnatal period secretory IgA antibodies are 
produced earlier than, and independently of serum IgA antibodies (South, 1971)    
IL-12 (and related 
antigen 
presentation 
Capacity for IL-12 secretion is deficient (Siegrist, 2001) 
Thymic function Response to thymic independent antigen by 18 months (Stein, 1992) 
 
 
1.4.1 Innate immunity in the neonate 
 
The systems mediating innate immunity have certain quantitative deficiencies that 
affect the newborns response to infections. The neutrophil storage pool in human 
neonatal bone marrow is considerably smaller than that of the adult (Christensen et 
al., 1982). Neonatal neutrophils ingest and kill bacteria as efficiently as their adult 
counterparts but adhesion, chemotaxis, lower enzymatic activity and signalling and 
subsequent migration of these cells to sites of infection is impaired (Wolach et al., 
1992). Further limitations occur at the levels of monocytes, macrophages, the 
complement system, NK and lymphocyte activated killer cell cytotoxicity, which 
remain below adult levels even after induction with exogenous interleukin 12 (IL-12) 
 15
and IL-15 (Neutra et al., 1996; Berger et al., 1990). The major components of innate 
immunity thus appear weakened in newborn infants. 
 
1.4.2 Neonatal T cell responses 
 
T cell responses in early life also appear to be impaired as infants succumb to serious 
infection with certain viruses such as herpes simplex and rubella (Schelonka et al., 
1998). Naive T cells require a much longer TCR triggering period compared with 
mature effector cells (Valitutti et al., 1997). TCR diversity is more limited during foetal 
and neonatal life than in adults (Schroeder et al., 1995; Gavin et al., 1995). 
Additionally, the functional capacity of T cells in the foetus and neonate is immature in 
that the neonatal T cells express a limited repertoire of lymphokines in response to 
activation (Wilson et al., 1992). The majority of human cord blood CD4+/CD8+ T cells 
present CD45RA+ naïve phenotype, whereas both the CD45RA+ and the 
memory/mature CD45RO+ phenotypes are represented in equal numbers in adult 
peripheral blood mononuclear cells (Kovarik et al., 1998). It is widely accepted that 
neonatal T cells are immunocompetent but that their differentiation is biased towards 
a Th2 profile under neutral conditions. It is not clear whether this Th2 bias can be 
attributed to the Th2 cytokine milieu of pregnancy, to altered interactions of APCs with 
T cells, or to both of these factors (Kovarik et al., 1998). 
 
1.4.3 Major cytokine profiles of the foetus and neonatal infant 
 
Neonatal monocytes and macrophages are qualitatively different from adult cells in 
that they are defective in the secretion of a variety of Th1-type cytokines. Nature 
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biased foetal immunity toward a Th2 polarisation which appears to be an evolutionary 
adaptation orchestrated via production of cytokines and other regulatory molecules 
(Marodi, 2006). The predominant production of Th2 cytokines in foetal and neonatal 
life appears to play a key role in damping the newborns innate immune responses 
(Trinchieri, 1995). Production of Th1 cytokines is reduced not only during foetal life 
but also after birth. Deficiency of IFN-γ production by neonatal T cells in response to 
mitogens or bacterial antigens has been well documented (Bryson et al., 1980; 
Wilson et al., 1986). A decreased production of IL-12 by cord mononuclear cells may 
be linked to IFN-γ deficiency in newborns (Lee et al., 1996). In early life there is 
diminished production of other cytokines as well such as IL-2, IL-4, IL-6, IL-13 and IL-
18, by neonatal cells which may result from the abundance of Th2 cytokines (Ribeiro-
do-Couto et al., 2001). The responsiveness of human neonatal monocytes and 
macrophages to individual cytokines differs significantly from that of adult cells and 
the defect in neonatal macrophage activation involves pathways downstream from 
ligand-binding events and includes signal transduction pathways (Marodi et al., 2001). 
An overall deficiency of certain cytokines may also explain why neonatal CD4+ cells 
have diminished capacity to provide help for immunoglobulin synthesis (Splawski et 
al., 1991). 
 
1.4.4 Antibody production in the neonate 
 
The humoral immune system remains relatively underdeveloped, with the neonate 
being almost entirely dependent upon passively acquired maternal antibody (Jaspan 
et al., 2006). IgG and IgA responses to pathogens are weak during the first year of 
life. Acquisition of full antigen responsiveness proceeds with the diversification of the 
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antibody repertoire, which reaches adult-like patterns between two to six months of 
life for IgM and possibly later for IgG (Kovarik et al., 1998). Immune responses to 
polysaccharide antigens are thymus independent (TI) and these responses to TI 
antigens develop late in infancy by about 18 months of age (Stein et al., 1992).  
 
1.4.5 IFN-γ production in the neonate 
 
The production of IFN-γ is impaired in early life (Wilson et al., 1986). Decreased 
production of IFN-γ by neonatal cells appears to be due to differences in their intrinsic 
capacity to produce IFN-γ and to differences in regulatory mechanisms (Wilson et al., 
1986). IFN-γ is a much more potent inducer of macrophages than IFN-α or β. In 
contrast to IFN-γ, IFN-α, and -β production by neonatal cells is similar to that by adult 
cells. Thus, decreased production of IFN-γ may be an important factor that 
predisposes the neonate to severe infection with intracellular pathogens (Wilson, 
1986). According to Burchett et al. (1998) a lag in IFN-γ production occurs in the 
neonate for at least the first two months of age. The capacity of T cells to produce 
IFN-γ and the number of memory T cells both increases over time (Sanders, 1988). 
The IFN-γ production of T cells is low because of limited exposure to foreign antigens. 
IFN-γ is produced in larger amounts by T cells that appear to have been previously 
activated in vivo by their interaction with suitably presented antigens. Lewis et al. 
(1990) concluded that reduced IFN-γ production by neonatal T cells was a functional 
phenotype established during intrathymic development and was primarily transcription 
 18
mediated. In previous reports, reduced IFN-γ production by mitogen activated 
leukocytes or T cells have been variously attributed to suppression mediated by  
CD4+ or CD8+ T cell populations (Seki et al., 1986; Haas et al., 1987). There is 
increasing evidence that memory T cells, defined as those that have been activated 
or primed by antigen are capable of increased levels of IFN-γ production, compared 
to antigenically naïve, virgin T cells (Wilson et al., 1986). The results of Taylor et al. 
(1985) showed that the neonatal macrophage is primarily responsible for the impaired 
IFN-γ by newborn cells. Research by Wilson et al. (1992) highlighted that the 
difference in expression of the IFN-γ gene could be due to differences in the structure 
of the chromatin or in methylation of critical sequences of the gene. 
 
1.5 HIV prevalence and maternal infant HIV-1 transmission  
 
At the end of 2006, a global total average of 39.5 million people, were living with 
HIV/AIDS (type 1 and 2). Of that total, an average of 4.3 million were newly infected 
in 2006. Although this data shows that HIV/AIDS remains a global problem, Southern 
Africa remains the epicentre of this epidemic: 32% of people with HIV worldwide live 
in Southern Africa and 34% of AIDS deaths globally occur here 
(http://www.mrc.ac.za/bod/DemographicImpactHIVIndicators.pdf). The latest data 
shows a 35% increase in HIV infection levels among pregnant women attending 
antenatal clinics. Even with an increase in the rollout of antiretrovirals and other 
preventative measures in place, worldwide current figures indicate that 26% of infants 
born to HIV (type 1 and 2) infected mothers are still becoming infected 
(http://data.unaids.org/pub/EpiReport/2006/04Sub_Saharan_Africa_2006_EpiUpdate
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_eng.pdf ). This would then mean that 74% of the infants born to these HIV (type 1 
and 2) infected mothers, make up the exposed uninfected (EU) group of the 
population. 
 
1.6 HIV-1 infection and innate and specific cellular immunity 
 
Children infected with HIV-1 display a variety of immune abnormalities which includes 
defects in the microbicidal response of phagocytic cells (Lazzarin et al., 1986 and 
Roilides et al., 1993), impaired neutrophil antifungal and bactericidal neutrophil 
activity . Quantitative depletion and impaired function of CD4+ T cells is a major factor 
contributing to HIV-1 associated immunosuppression (Fauci, 1998). Functional 
studies by Shearer and Clerici (1991), show a progressive loss in T cell proliferative 
responsiveness with disease progression, firstly to recall antigens, then alloantigen 
and mitogen respectively. Antiretroviral interventions in preventing mother-to-child 
transmissions were introduced as early as 1994. Chougnet et al. (1998, 2001) 
conducted two different studies to assess whether treatment of HIV-1 positive 
children by antiretroviral drugs for a six month period and a two year period 
respectively would improve immune function. It was determined that (i) there was a 
marked increase in the proliferative response and skin reactivity to recall antigens, (ii) 
viral loads decrease significantly, (iii) CD4+ T-lymphocytes counts increased but (iv) 
restoration of defective cellular immune responses did not occur.  
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1.7 The HIV-1 exposed uninfected infant 
 
Children born to HIV-1 infected mothers are at risk of acquiring infection in utero 
(while in the womb), intrapartum (during the birthing process) or postpartum (through 
breastfeeding) (Magder et al., 2005; Ahmed, 1996; Douglas et al., 1992). Significant 
immunological changes associated with intrauterine HIV-1 exposure have been 
described in HIV-1 uninfected infants born to HIV-1 infected mothers (Kuhn et al., 
2002) such as sensitisation to HIV-1 recombinant antigens resulting in cell–mediated 
immune responses (Borkowsky et al., 1990) and the presence of CTL effector 
responses in the peripheral blood of these children (Cheynier et al., 1992). Factors 
that can influence the outcome of HIV-1 exposure in children born to HIV-1 infected 
mothers have been reviewed by Tiemessen and Kuhn (2006) and are presented in 
Fig.1.2. These authors further mention that (i) the integrity of innate immune functions 
could contribute towards the development of HIV-1 specific immunity, (ii) CC 
chemokines contribute to protective immunity against HIV-1 and to the attenuation of 
disease progression once infection is established, and (iii) children by virtue of their 
genetic similarity to their mothers can inherit a virus that has evolved to evade HLA-
mediated responses.  
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HIV-1 exposure/
infection
Immune Capability
Innate immune system
Cellular Component
Dendritic cells
Monocytes/macrophages
Neutrophils
NK cells
NKT cells
Humoral component
Complement
Acute phase proteins
Cytokines
Chemokines
Antimicrobial proteins
Adaptive immune 
system
Cellular component
T cells (CD4 and CD8)
B cells
Humoral component
Antibodies
Outcomes
Efficient immune response
•Infection prevented in the EU infant
•Infection contained in the HIV-1 infected infant
Deficient immune response
•Infection established
•Rapid disease progression in the HIV-1 infected child
Age related immune
maturation
Host
Genetics
Figure 1.2 Factors (host genetics, maturational immune development and HIV-1 
exposure/infection) influencing the immune capability and subsequent outcomes 
of HIV-1 exposure/infection in children. Cellular and humoral components of 
innate and adaptive immune systems are shown. NK-natural killer cells; NKT-
natural killer T cells (Reproduced from Tiemessen and Kuhn, 2006) 
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With the increasing use of ART drugs to prevent mother-to-child transmission of HIV-
1, large numbers of infants are exposed, however there is the consequent risk of ART 
toxicity. Studies by Pacheco et al. (2006), Le Chenadec et al. (2003) and El Beitune 
et al. (2004) show that (i) there is a persistent inhibition of haematopoietic cells up to 
the age of 18 months (ii) haemoglobin concentrations, neutrophil, lymphocyte, and 
CD4+ T cells are lower at age 0-2 months in infants exposed to ART than those who 
are not. At age 6-24 months differences in lymphocyte and CD4+ T cell counts 
persisted whereas CD8+ T cell counts were significantly decreased (iii) combinations 
of ART drugs were associated with larger such decreases than occurs with 
monotherapy up to 15 months of age. These immunological contraints as well as the 
responses mentioned in section 1.7.1 and 1.7.2 are especially noteworthy given the 
immaturity of the neonatal cellular immune response.  
 
1.7.1 HIV-1 specific (acquired) immune responses among EU infants 
 
HIV-1 specific responses have been demonstrated in cord blood and peripheral blood 
of uninfected infants (1-18 months of age), and include measures of antigen-specific 
CD4+ T helper cell activity (lymphoproliferative and IL-2 production studies), CD8+ 
cytotoxic T-lymphocyte (CTL) responses, and CD8+ noncytolytic HIV-1 suppressor 
activity. Collectively these findings demonstrate immunological memory suggestive of 
prior exposure to HIV (Kuhn et al., 2002). At least two studies have observed 
associations between the detection of responses to HIV-1 peptides at birth and lack 
of infection (Clerici et al., 1993; Wasik et al., 1999). Confirming and strengthening 
these studies was one other prospective, epidemiological study conducted in a 
breastfed population (which can be likened to a natural challenge study) which 
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directly tested in a longitudinal manner, whether or not HIV-1 specific responses are 
associated with protection given subsequent viral exposure (Kuhn et al., 2001). All 
these studies have utilized some of the same gp160 peptides (T1, T2, TH4 of 
conserved regions and P18 MN and P18 111B of variable regions) (Berzofsky et al., 
1991; Hale et al., 1989; Cease et al., 1987) to elicit T helper cell responses. Detection 
of an HIV-1 specific immune response to these gp160 peptides at birth therefore 
provides an important marker of protective immunity to HIV-1 in the infant. 
 
1.7.2 Non-specific (innate) immune responses in EU infants  
 
In further support of greater antigenic stimulation occurring in HIV-exposed uninfected 
infants compared to their unexposed uninfected counterparts is the fact there are 
notable alterations in a number of non-specific immune parameters. Examples 
include elevations in populations of activated helper T cells (CD4+ HLA-DR+ CD38+) 
and memory helper T cells (CD4+ CD45RA- RO+) (Rich et al., 1997), a trend towards 
increased levels of soluble L-selectin in the first two days of life, shed after 
lymphocyte activation by antigen-presenting cells (Kourtis et al., 2000), transient 
expansions in the T cell receptor beta-chain variable region (Soudenys et al., 2000), 
reduced IL-12 production in cord blood (Chougnet et al., 1996), reduced production of 
IL-2 in phytohaemagglutin (PHA)-stimulated peripheral blood mononuclear cells 
(PBMC) (Rich et al., 1997), elevated PHA-stimulated IFN-γ and IL-10 in cord blood 
leukocytes (Nicastri et al., 1999), and raised serum levels of IL-7, a cytokine important 
in thymopoeisis, in newborn and older uninfected children of HIV-infected mothers 
(Clerici et al., 2000). This together with evidence of alterations of various cell subsets 
(increased memory cells, altered CD4+/CD8+ ratios, elevated numbers of activated 
 24
CD38+CD8+cells and CD3+/4-/8- cells) in the same study suggest that T cell 
homeostasis is impaired in these children. Some of these abnormalities persist with 
age and raise the question as to whether these children, through exposure to HIV-1, 
may be susceptible to other diseases (Clerici et al., 1993), or may have altered 
disease courses with other organisms, or even altered responses to some vaccines. 
 
1.8 Aims and objectives of the study 
 
It was the purpose of this study to contribute towards understanding immune 
responsiveness, as measured by IFN-γ production, in uninfected infants born to HIV-
1-seropositive mothers. The study as designed, addresses consequences of HIV-1 
exposure on the development of IFN-γ responses in early life. This is important as 
prenatal exposure to HIV-1 may affect the development of cell mediated immune 
responses by priming T cells, a factor that could influence the outcome of subsequent 
vaccine responses or of subsequent infectious events.  
 
Specific objectives: 
1. To determine whether exposure to HIV-1 in utero and at birth influences IFN-γ 
production in the infant as measured at birth and at six weeks of age. 
2. To assess whether in utero HIV-1 exposure or exposure to maternal nevirapine 
influences alterations in numbers of different leukocyte cell subtypes. 
3. To identify the cell types responsible for producing IFN-γ (using PHA and BCG 
as stimuli). 
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Comparisons have been drawn that take into account two scenarios in the context of 
mother-child relationship: (1) no exposure to HIV-1 (uninfected control - mother and 
infant) and (2) maternal HIV-1 infection and the EU infant. 
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CHAPTER 2 
 
 
IFN-γ production in whole blood of mothers and their infants using PHA and 
BCG as stimuli  
 
2.1 Introduction 
 
Clinical trials conducted in developing countries have proven that short-course 
antiretroviral therapy (ART) can substantially reduce MTCT of HIV-1 (Connor et al., 
1994; Guay et al., 1999; Taylor et al., 2000; Gray et al 2005). Despite the availability 
of such short-course prophylactic interventions it is estimated that during 2006 64 000 
babies became infected through MTCT in South Africa (Dorrington et al., 2006). Even 
in the absence of ART drugs, most infants (65%-85%) of HIV-1 infected mothers do 
not become infected (Kuhn et al., 2002). Infants that remain uninfected despite   
exposure to maternal HIV-1 (intrauterine, intrapartum or through breastmilk) have 
been referred to as “exposed uninfected” (EU) infants. These infants exhibit many 
HIV-1-specific responses and non-specific/innate immune responses elicited through 
in utero priming of cells and remain uninfected despite challenge again at the time of 
delivery and ongoing exposure to HIV-1 during breastfeeding (Kuhn et al., 2002). 
Chougnet et al. (2000) suggest that the maternal environment and/or exposure in 
utero to HIV-1 products influence the newborns immune response and that the 
differences between infants born to HIV-1 positive and negative women may persist.  
In fact, HIV-1-specific T cell responses have been reported following low dose 
exposure to HIV-1 with a decrease in this T cell function being reported in subsequent 
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months following termination of the exposure to HIV-1 from the mother (Shearer and 
Clerici, 1996). Given the immaturity of the neonatal cellular immune response, the 
immunological differences observed in HIV-1 exposed uninfected infants are 
especially noteworthy.  
 
We aimed, in this section of the study, to contribute towards understanding immune 
responsiveness, as measured by IFN-γ production, in uninfected infants born to HIV-1 
seropositive mothers. Furthermore, we aimed to address consequences of HIV-1 
exposure on the development of IFN-γ responses in early life. This was done by 
measuring IFN-γ responses in whole blood cultures that were set up with samples 
collected at birth and at six weeks of age from infants born to HIV-1 infected and 
uninfected mothers. 
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2.2 Materials and Methods 
 
2.2.1 Study subjects and samples 
 
The collection of samples was done at Chris Hani Baragwanath Hospital (CHBH), 
Soweto, South Africa. The study population recruited included women participating in 
the Perinatal Mother-to-child Transmission (PMTCT) program and included 13 HIV-1 
uninfected mothers and their newborns and 120 HIV-1 infected women and their 
newborns. The women were enrolled between January 2003 and March 2003 and 
their HIV-1 infection status was determined prior to enrolment. All mothers and their 
infants received a standard regimen of one dose each of nevirapine (sdNVP) 
(mothers being given a single dose of NVP (200 mg) at the time of delivery and 
infants being administered a single dose of NVP (2 mg/kg) within 48 hours (hrs) of 
birth). Infants with a birth weight of less than 2500 g or with substantial medical 
problems at birth were excluded from the study. Infants that did not report for the six 
week follow-up were also excluded. Samples were only available for this study for 11 
HIV-1 uninfected (control) mothers and their infants and 91 HIV-1 EU infants and their 
HIV-1 infected mothers. 
 
Peripheral blood was collected in preservative-free ethylenediamine tetra-acetic acid 
(EDTA) vacutainer tubes (Becton Dickinson) from the mother (10 ml) at delivery and 
from the infants (5 ml) within 48 hrs of birth. The blood was transported to the Cell 
Biology Laboratory at the National Institute for Communicable Diseases, and 
processed within three hrs of collection. A further blood sample was collected from 
the infant at six weeks of age. HIV-1 DNA PCR tests were carried out to establish 
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infection status using the Roche Amplicor HIV-1 DNA PCR assay version 1.5 (Roche 
Diagnostic Systems, Inc, New Jersey, USA). For the purpose of this study all infected 
infants were excluded. Written informed consent was obtained for participation of the 
mothers and their infants. Ethical approval was obtained from the Committee for 
Research on Human Subjects of the University of the Witwatersrand (Appendix F). 
 
2.2.2 Ex vivo whole blood stimulation assay 
 
Maternal and infant whole blood, collected in section 2.2.1, was diluted 1:10 in sterile 
RPMI 1640 tissue culture medium supplemented with 2 mM L-glutamine (Sigma 
Aldrich, St Louis, MO, USA), 100 U/ml penicillin (Sigma-Aldrich, St Louis, MO, USA) 
and 100ug/ml streptomycin (Sigma-Aldrich, St Louis, MO, USA). Diluted blood (180 µl 
per well) was dispensed in triplicate into 96-well flat-bottomed plates for each 
stimulant as well as for control samples, to which only medium was added. Cultures 
were stimulated with 20 µl of either phytohaemagglutinin (PHA; final concentration 5 
µg/ml) or live attenuated Mycobacterium bovis bacillus Calmette-Guérin (BCG: 
Danish strain 331, Statens serum Institute, Denmark; final concentration 15 µg/ml). 
PHA cultures were incubated at 37oC in a humidified 5% CO2 incubator for 3 days, 
and BCG cultures for 7 days. Culture supernatants were harvested at these time 
points and stored at -70°C prior to testing by enzyme linked immunosorbent assay 
(ELISA). 
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2.2.3. Quantitation of IFN-γ from culture supernatants using ELISA 
 
The amount of IFN-γ produced in control (medium only), PHA and BCG stimulated 
cultures was determined from the culture supernatants using the commercially 
available IFN-γ ELISA kit (BD Biosciences Pharmingen, San Diego, California), using 
pairs of monoclonal antibodies, as described by the manufacturer. The optical density 
of each well was determined within 30 minutes of addition of the stop solution using a 
microplate plate reader (Organon Teknika Microwell system 230s reader, Labotec 
GMBH, Austria) set at 450 nm with a correction wavelength of 570 nm. The mean 
absorbance for each set of duplicate standards was calculated. The mean zero 
standard absorbance was subtracted from each of the samples. The concentration of 
each unknown sample was determined by calculating the concentration of IFN-γ 
corresponding to the mean absorbance from the standard curve run with each assay. 
Where samples required a two - a 100-fold dilution the IFN-γ concentration was 
determined by multiplying the concentration read from the standard curve by the 
dilution factor. Results for PHA and BCG were obtained by subtracting the medium 
control result. Results reflected the total amount of IFN-γ produced and were 
expressed in pg/ml. The detection limit for the IFN-γ ELISA was 5 pg/ml.  
 
2.2.4 Statistical tests  
 
A logarithmic transformation of the concentrations was used to normalize the 
distribution. The non-parametric Mann-Whitney test was used to determine whether 
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there were any significant differences in IFN-γ production between the different study 
groups. Statistical analyses were performed using SPSS software (version 11.0), 
SPSS Inc., Chicago, IL). All statistical tests were two-tailed and considered significant 
at P<0.05.  
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2.3 Results 
 
2.3.1 IFN-γ production in the EU infant 
 
The impaired protection of newborn babies against infections has been attributed to a 
deficient secretion of cytokines such as IFN-γ. To determine whether exposure to 
HIV-1 in utero and at birth has any effect on IFN-γ production, whole blood cultures of 
newborn infants and their corresponding mothers were set up according to the 
procedure described in section 2.2.2, that is, cultures were either unstimulated or 
stimulated with PHA and BCG and the amount of IFN-γ produced measured in culture 
supernatants by ELISA (section 2.2.3). 
 
Newborn EU infants produced significantly higher levels of IFN-γ than the unexposed 
control group when stimulated with either PHA (P<0.001) (Fig. 2.1A) or BCG 
(P=0.005) (Fig. 2.1B). No significant differences in IFN-γ production were observed in 
either HIV-1 uninfected or HIV-1 infected mothers when PHA (Fig. 2.1C) or BCG (Fig. 
2.1D) were used as a stimulus. 
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Fig. 2.1 IFN-γ levels measured from whole blood cultures of newborn 
control and EU infants in response to PHA (A) and BCG (B), and from 
their corresponding control and HIV-1 infected mothers in response to 
PHA (C) and BCG (D) 
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2.3.2 IFN-γ production of infants at birth and six weeks of age 
 
To address the question whether IFN-γ production over time was different between 
uninfected control and EU infants, whole blood cultures (unstimulated and stimulated 
with PHA and BCG) were set up at birth and at 6 weeks of age. In addition, cultures 
were also set up for HIV-1 infected mothers and HIV-1 uninfected mothers at these 
same time points.  
  
HIV-1 control (unexposed) infants produced significantly more IFN-γ at six weeks of 
age  compared to birth when stimulated with either PHA (P<0.001) (Fig. 2.2A) or BCG 
(P<0.001) (Fig. 2.2B). Similarly, EU infants exhibited elevated levels of IFN-γ at six 
weeks compared to their birth levels to both stimuli (PHA, P=0.001, Fig. 2.2C; BCG, 
P<0.001, Fig. 2.2D). Interestingly, while we have shown that IFN-γ production in 
response to PHA and BCG is significantly higher in newborn (birth) EU than control 
(birth) infants (Fig. 2.1A and B), by six weeks, control infants produced significantly 
more IFN-γ in response to PHA only (P=0.031; BCG P>0.05) compared to EU infants 
(statistical data not shown in the Figures). These results suggest in utero exposure to 
HIV-1 influences the immune response of EU infants. 
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Fig. 2.2 IFN-γ from whole blood cultures of control infants at birth and 
six weeks (6 wks) in response to PHA (A) and BCG (B); and in EU 
infants at birth and six weeks in response to PHA (C) and BCG (D) 
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2.3.3 Maturation of immune responses from birth to six weeks in HIV-1 
unexposed and EU infants using PHA and BCG as stimuli 
 
Since the results in section 2.3.2 suggested that in utero and birth exposure to HIV-1 
influences immune responses, it was interesting therefore to determine the extent of 
this effect by examining how immune responses developed from birth to six weeks of 
age in EU and control infants. This was achieved by measuring the change in 
producing capacity, in response to PHA and BCG in control and EU infants. All 
control infants (100%) responded with increased IFN-γ production when cultures were 
stimulated with PHA at 6 weeks relative to their corresponding birth sample, while 
only 60% of the EU infants demonstrated such an ability (Fig. 2.3). Furthermore, 91% 
of control infants exhibited increased immune response to BCG through vaccination 
given at birth while only 79% of EU infants could induce such responses (Fig. 2.3). 
EU infants tended to exhibit the widest range of  patterns of responses with age viz. 
most infants showing either no change in response or an increased/decreased IFN-γ 
response when stimulated with either PHA or BCG (Fig. 2.3). A BCG response was 
already present in 48% (44/91) of EU infants at birth and 14% (13/44)) showed a 
decrease subsequent to vaccination whereas 34% (31/44) showed an increase 
subsequent to BCG vaccination (data not shown in Figures). 
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2.4 Discussion 
 
Newborns and infants are particularly susceptible to infections and this has been 
ascribed to deficient immunoresponsiveness. Th1 responses, characterized by the 
production of IFN-γ, have been considered to be required for protection against 
mycobacteria and viruses. Immaturity of T cell immunity and a bias to Th2 responses 
have been considered to be obstacles to successful neonatal vaccination. 
Specifically, T cell dependent responses have been shown to be biased towards a 
Th2 phenotype ascribed to particular conditions of antigen presentation at priming 
(Delespesse et al., 1998). Furthermore, the production of interferons, IL-12/IL-23 and 
IL-18 as well as other pro-inflammatory cytokines are reportedly deficient in neonates 
(Kovarik et al., 1998; Marodi, 2006). This study was designed to investigate the 
production of the immune cytokine, IFN-γ in response to PHA and BCG vaccine, 
among control infants and those exposed to HIV-1 in utero and to evaluate the 
maturation of the cellular immune response in the first six weeks of life in these two 
groups of infants. 
 
A whole blood assay was the method of choice over other alternative assays e.g. the 
lymphocyte proliferation assay, cytokine detection with peripheral blood mononuclear 
cell cultures or the enzyme linked immunospot assay (ELISPOT) due to it (i) being 
simple for assessing immune cytokine profiles, (ii) showed little inter-assay variability, 
(iii) could be performed on small amounts of blood that did not require sophisticated 
processing or the purchase of expensive materials and equipment (Pai et al., 2004; 
Scholvinck et al., 2004) and (iv) has been proven to reliably detect IFN-γ responses to 
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mitogenic stimuli and to more accurately reflect the in vivo situation (Hussain et al., 
2002; Scholvinck et al., 2004). 
 
Our results have shown that (i) newborn infants exposed in utero to HIV-1 produce 
significantly more IFN-γ than unexposed infants following PHA or BCG stimulation, (ii) 
overall an increase in IFN-γ producing capacity occurs within the first six weeks of life 
in both control and EU infants, (iii) BCG induced responses are more prevalent in 
newborn EU infants but by six weeks, maturation of responses of EU and control 
infants was similar, (iv) a lesser percentage of EU infants than control infants are able 
to respond with an increase in IFN-γ production at six weeks in response to PHA and 
BCG, (v) an interesting and unexpected observation between EU and control infants 
(data not shown) was that an IFN-γ response to BCG at birth is already present in 
48% of the EU infants.  
 
In support of our findings, Vekemans et al. (2001) have reported the median IFN-γ 
production to BCG and PHA to increase significantly in both HIV-1 exposed and 
unexposed children from birth to six weeks of age reflecting the establishment of an 
immune response (following BCG vaccination) and maturation of the infant’s immune 
response (response to PHA). Importantly, these observations suggested that 
immunological differences observed at birth between HIV-1 exposed and HIV-1 
unexposed infants may persist for at least the first six weeks of life.  
 
Increased IFN-γ production may be accounted for by increased priming of the 
immune system as reflected by increased immune activation. The increased immune 
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activation, reported in HIV-1 exposed uninfected infants may be a consequence of in 
utero exposure to HIV-1 antigens and/or exposure to antigens related to other 
infections in their HIV-1 infected mothers (Rich et al., 1997). In fact, it has been 
reported that levels of immune activation markers, measured from cord blood plasma, 
are elevated in EU infants and that levels of the immune activation markers are 
further elevated in EU infants exposed to single-dose NVP when compared to their 
drug unexposed counterparts (Schramm et al., 2006). Thus, exposure to drugs may  
be sufficient to drive an already activated immune system into a further 
anergic/immunodeficient state (Schramm et al., 2006). The inability or decreased 
ability of some EU infants to produce IFN-γ at 6 weeks may indicate a lack of immune 
response to BCG, a lack of maturation of the cellular immune response or might well 
be a consequence of T cell anergy, an inability of the immune system to develop or a 
‘fast-tracked’ immune response viz. the immune capability of newborn EU infants (as 
shown by higher IFN-γ production) compares to that of a six week old infant who has 
not similarly been primed through HIV-1 exposure. The already present BCG 
response in a substantial proportion of the EU infants at birth is interesting and most 
likely is due to an innate/non-specific response to BCG (which may be triggered by 
the greater state of immune activation in EU vs control infants), as an adaptive 
response would require previous exposure to BCG and would not be instantaneous, 
requiring time to develop. 
 
The study as described has a few limitations, namely, (i) the follow-up period was at 
six weeks and no further longitudinal time points were assessed. It would have been 
interesting to determine, for EU infants that either showed no responses or decreased 
responses, the time points when immune responses could be measured or for infants 
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that did show responses the length of time that such responses would persist. The 
long term effect of in utero exposure definitely requires further research, (ii) a 
disadvantage of the whole blood assay is that the cell types responsible for the IFN-γ 
production could not be identified. In Chapter 4 this latter point is addressed using 
intracellular cytokine (ICC) staining to identify the predominant IFN-γ producing cell 
types.  
 
Early immunization is required to protect infants from pathogens to which they are 
exposed after birth but this is limited by the immaturity of the neonatal immune 
system. Vaccination of newborns with BCG has been shown to result in the 
development of Th1-type responses (Marchant et al., 1999) however our findings 
indicate that prenatal exposure to HIV-1 influences the immune response to both PHA 
and BCG which could influence both the capacity to respond to early immunization or 
result in altered thresholds of responsiveness which could then influence the outcome 
of subsequent infectious events or vaccine responses. These findings may have 
important implications for the optimal timing and effectiveness of BCG vaccination in 
these infants and warrants careful immunological evaluation of Tuberculosis 
vaccines. While the clinical importance of these findings remains unknown, further 
investigation is warranted as the observed immunological changes may result in 
altered susceptibility to infectious diseases in this already vulnerable population. 
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CHAPTER 3 
 
 
Haematological changes in infants born to HIV-1 uninfected and HIV-1 infected 
mothers 
 
3.1 Introduction 
 
It has long been shown that the human immune system is functionally less mature at 
birth and within the first years of life, undergoes a process of sequential development 
that is both programmed genetically and stimulated externally by antigen exposure 
(Erkeller-Yuksel et al., 1992). In particular, neonates are highly susceptible to 
bacterial, viral, and parasitic intracellular pathogens. This profound neonatal 
immunodeficiency can be attributed to immaturity and dysregulation of specific T cell 
mediated immunity, lack of memory T cells, and dysregulation of expression and 
production of specific lymphokines, cytokines and inflammatory mediators (Suen et 
al., 1998). Compared to adults, infants have increased numbers of lymphocytes as 
well as different distributions of the major lymphocyte subsets (Plaeger-Marshall et 
al., 1993). In Chapter 2, we looked at IFN-γ production from whole blood cultures of 
HIV-1 uninfected mothers and their infants as well as HIV-1 infected mothers and 
their EU infants. It was shown that EU infants produce significantly more IFN-γ at birth 
compared to controls indicative that T cell responsiveness may develop earlier due to 
in utero HIV-1 priming. It was interesting therefore to question, using a leukocyte 
haematology analyzer, whether differences in proportions or absolute lymphocyte 
blood counts (particularly since cells such as T cells and NK cells known to be major 
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producers of IFN-γ are in this cell compartment) might account for the disparities 
observed in the IFN-γ production between the infant groups or whether exposure to 
short course ART treatment (to prevent maternal HIV-1 transmission) may influence 
blood cell counts that could in turn affect  IFN-γ production levels. 
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3.2 Materials and Methods 
  
3.2.1 Study subjects and samples 
 
The study subjects were recruited at CHBH, Soweto, South Africa and from 
Coronation Women and Children Hospital (CWCH), Johannesburg, South Africa. 
These participants formed part of the HIV Protective Immunity and Perinatal 
Exposure (PIPE) study. The participants were recruited from women identified as 
HIV-1 seropositive as part of a voluntary counselling and testing programme. Women 
were enrolled within 48 hrs of delivery and were given a single dose of NVP 
(sdNVP)(200 mg) to prevent maternal transmission of HIV-1 at the onset of labour. 
For various reasons some mothers did not take the dose of NVP. This nested case-
controlled study comprised 83 HIV-1 infected mothers and their EU infants and 14 
HIV-1 uninfected mother-child pairs. Of the HIV-1 infected mothers, only 72 mothers 
took NVP. Thus, only infants whose mothers had taken the dose of NVP at the onset 
of labour were exposed to NVP during labour and delivery. However, all infants were 
given a dose of NVP (2 mg/kg) within 48 hrs of birth to prevent postpartum 
transmission. Peripheral blood (10 ml) was collected by venipuncture from the mother 
at delivery and from the infants (5 ml) within 48 hrs of birth in preservative-free five ml 
EDTA vacutainer tubes, and again at six weeks. The blood was transported to the 
National Institute for Communicable Diseases Cell Biology laboratory and processed 
within three hrs of collection. Written informed consent was obtained from all 
participants and ethical approval was obtained from the Committee for Research on 
Human Subjects of the University of the Witwatersrand (Appendix F). 
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HIV-1 DNA PCR tests were carried out at to establish infection status and timing of 
infection using the Roche Amplicor HIV-1 DNA PCR assay version 1.5 (Roche 
Diagnostic Systems, Inc, New Jersey, USA). Maternal viral load was measured in 
plasma using the Roche Amplicor RNA Monitor assay (Roche Diagnostic Systems, 
Inc, New Jersey, USA) with a lower detection limit of 400 RNA copies/ml. 
 
3.2.2 Full blood counts 
 
A full blood count was performed on the maternal and infant blood samples within 
three hrs of blood having been drawn from patients, using a fully automated AcT 5 diff 
haematology analyser (Beckman Coulter Inc, Fullerton, CA) according to the 
manufacturer’s protocol. The instrument is automated to draw up 52 µl of sample for 
analysis. The instrument differentiated monocyte, neutrophil, eosinophil and basophil 
populations based on absorbance patterns produced by differential cytochemical 
staining of their granules versus volume. Reference controls (low, medium and high; 
Beckman Coulter Inc, Fullerton, CA) were routinely used to confirm and monitor 
instrument accuracy and performance by providing measurements for counting, 
sizing, haemoglobin determination and white blood cell differentiation. For each 
sample a report was automatically printed and the data on the cell types was 
presented as a percentage as well as an absolute number per microlitre (µl). 
Specimen results were accepted when the control ranges fell within those specified 
for the reference controls. Specimens whose results fell out of the range of 
determination were diluted (1:2 or 1:4 in saline) and the dilution factor taken into 
account when leukocyte counts for these samples were analysed.    
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3.2.3 Statistical Tests 
 
The non-parametric Mann-Whitney test was used to determine whether there were 
any significant differences in the proportions and absolute counts between the 
groups. The Wilcoxon test was used to determine whether there were any significant 
differences in the proportions and absolute counts of the different leukocyte 
populations of the groups at birth and six weeks. Statistical analyses were performed 
using SPSS software (version 11.0, SPSS Inc., Chicago, IL). All statistical tests were 
two-tailed and considered significant at P<0.05.  
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3.3 Results 
 
3.3.1 Changes in infant leukocyte types at birth and at six weeks  
 
The immune system of the young child undergoes maturation and development that 
is reflected in qualitative and quantitative changes in the peripheral blood (Jaspan et 
al., 2006). It was interesting therefore to compare the proportions and absolute counts 
of the different leukocyte types (neutrophils, lymphocytes, monocytes, eosinophils 
and basophils) of control and EU infants at birth and six weeks later (Table 3.1 and 
Fig. 3.1 A-D). In the control group of infants, lymphocyte and eosinophil proportions 
increased significantly over the first six weeks of life while neutrophil and basophil 
proportions decreased significantly. Proportions of monocytes remained unchanged 
over the first six weeks. Similarly, amongst EU infants, proportions of all leukocyte 
types, with the exception of monocytes, changed significantly (increased or 
decreased) over the first six weeks of life (Fig. 3.1 A-D). Particularly significant are the 
differences in the absolute counts of EU infants relative to control infants (Table 3.1). 
Whilst absolute counts of all leukocyte types are significantly altered from birth to six 
weeks amongst EU infants, only neutrophil, monocyte and basophil absolute counts 
of control infants change significantly from birth to six weeks. Importantly, no 
significant differences could be demonstrated between the absolute counts of the 
leukocyte types of birth infants (control and EU groups). At six weeks however, only 
the absolute eosinophil counts of EU infants were found to be significantly elevated 
compared to control infants. Notably, the absolute counts of the lymphocytes did not 
change significantly when comparing control and EU infants at birth (P>0.05) or 
control and EU infants at six weeks (P>0.05) (Fig. 3.2), although there was a trend 
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that EU infants have higher absolute lymphocyte counts at 6 weeks than control 
infants. Only the EU infants showed significantly increased absolute lymphocyte 
counts between birth and six weeks (P<0.001).  
 
Table 3.1 Absolute leukocyte counts of birth and 6 week samples of mothers and 
their infants 
Leukocyte type  Infant 
Median (IQR) Control EU 
n 14 83 
 Birth 6 wks P Birth 6 wks P 
Units (x103/µl)       
White blood cells  14.4 
(12.0-20.7) 
7.5 
(6.8-9.6) 
0.007 15.5 
(13.1-18-3) 
9.4 
(7.0-11.8) 
<0.001 
Neutrophils 9.0 
(6.0-11.3) 
1.8 
(1.4-2.3) 
0.001 9.1 
(7.0-10.9) 
1.9 
(1.4-2.6) 
<0.001 
Lymphocytes 4.5 
(2.7-5.2) 
4.8 
(3.7-6.5) 
>0.05 3.6 
(3.0-4.4) 
5.7 
(4.5-7.7) 
<0.001 
Monocytes 1.3 
(1.1-2.5) 
0.7 
(0.5-1.5) 
0.016 1.5 
(1.2-2.0) 
1 
(0.6-1.4) 
<0.001 
Eosinophils 0.2 
(0.14-0.3) 
0.31 
(0.2-0.4) 
>0.05 0.3 
(0.2-0.4) 
0.21 
(0.1-0.4) 
0.015 
Basophils 0.4 
(0.31-1.1) 
0.1 
(0.1-0.2) 
0.001 0.5 
(0.3-1.5) 
0.1 
(0.1-0.2) 
<0.001 
 Mother 
Median (IQR) Control Infected 
n 14 83 
 Birth 6 wks P Birth 6 wks P 
Units (x103/µl)       
White blood cells 12.7 
(9.5-19.8) 
5.6 
(3.9-7.5) 
0.004 10.3  
(8.4-15.8) 
4.9  
(4.1-6.1) 
<0.001 
Neutrophils 9.5 
(6-13.2) 
2.5 
(1.5-3.8) 
0.002 6.9 
(5.3-10.8) 
2.3 
(1.7-3.1) 
<0.001 
Lymphocytes 2.3 
(1.8-2.9) 
2.3 
(1.6-2.7) 
>0.05 2.3 
(1.8-2.7) 
1.9 
(1.6-2.5) 
0.001 
Monocytes 0.8 
(0.6-1.4) 
0.3 
(0.3-0.5) 
0.009 0.8 
(0.5-1.1) 
0.4 
(0.3-0.5) 
<0.001 
Eosinophils 0.22 
(0.1-0.4) 
0.2 
(0.08-0.3) 
>0.05 0.22 
(0.1-0.3) 
0.1 
(0.07-0.2) 
>0.05 
Basophils 0.13 
(0.07-0.2) 
0.1 
(0.03-0.07) 
>0.05 0.13 
(0.05-0.1) 
0.03 
(0.02-0.05) 
<0.001 
Statistical differences between birth and 6 wk samples are presented  
 
1
 P=0.035, EU infants versus control infants at six wks 
2
 P=0.018, infected mothers versus C mothers at delivery 
3
 P=0.037, infected mothers versus C mothers at delivery 
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Fig. 3.1 Proportions of leukocyte types in control birth infants (A), control 6 week 
old infants (B), EU birth infants (C) and EU 6 week old infants (D). Significant 
changes (data presented between the pie charts) in the proportions of the leukocyte 
types are shown for the control and EU infants from birth to 6 weeks and across 
groups at similar time points 
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Fig. 3.2 Comparison of absolute lymphocyte counts of control (C) and EU infants 
at birth and at six weeks 
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3.3.2 Changes in maternal leukocyte counts in control and HIV-1 infected 
mothers following delivery and six weeks later 
 
Immune responses in pregnant mothers are considered to be biased towards Th2 
cytokine expression. It was therefore interesting to establish how leukocyte types 
change after delivery and to establish the extent of these changes by comparing HIV-
1 uninfected mothers to those of HIV-1 seropositive mothers (Fig. 3.3 A-D and Table 
3.1). In control mothers, six weeks after delivery, proportions of neutrophils were 
significantly decreased and lymphocyte and eosinophil proportions significantly 
increased. This was similarly observed in HIV-1 positive mothers. Within the first six 
weeks, absolute counts of neutrophils, lymphocytes, monocytes and basophils of 
HIV-1 infected mothers were significantly altered from their counts following delivery 
(Table 3.1). This was only true for the absolute neutrophil and monocyte counts of 
uninfected mothers. HIV-1 positive mothers had significantly reduced absolute counts 
of eosinophils and basophils compared to uninfected mothers at birth, however, these 
differences were resolved six weeks post partum.  
 
3.3.3 Haematological changes in mothers who received single dose NVP at the 
onset of labour and their infants 
 
In vitro studies using clinically relevant concentrations of antiretrovirals e.g. zidovudine 
(AZT) have reported reduced responsiveness of PBMC to mitogen and a decreased 
ability to proliferate (Heagy et al., 1991). It was therefore interesting to determine 
whether short exposure to NVP (maternal dosage given at the onset of labour; infants 
exposed to the dose given to the mother and a further dose given within 48 hrs of 
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birth), could significantly impact on the composition of maternal or infant leukocyte 
types at birth and if so whether these differences would persist over time. 
 
When maternal leukocytes were compared between mothers that received sdNVP 
and those who did not (Table 3.2) the absolute blood counts did not significantly differ 
at either birth or six weeks later suggesting that sdNVP exposure does not impact on 
maternal blood counts. Infants exposed to NVP given to the mother at the onset of 
labour have significantly elevated basophil counts (P=0.043) at birth. By six weeks 
this effect was lost and leukocyte blood counts of infants exposed to maternal NVP 
were not significantly different from counts of infants given NVP within 48 hrs of birth. 
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Fig. 3.3 Proportion of leukocyte types in control mothers at delivery (A), control 
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charts) in the proportions of the leukocyte types are presented for the control and 
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Table 3.2 Significant differences in the absolute leukocyte counts of mothers 
and their infants distinguished on NVP versus no NVP exposure 
Effects of NVP on leukocyte types of mothers and infants at birth and six wks 
 Mother1 EU infant2  
Leukocyte type NVP vs no NVP 
birth 
P 
NVP vs no NVP 
6 wks 
P  
NVP vs no NVP 
birth 
P  
NVP vs no NVP 
6 wks 
P 
White blood 
cells 
>0.5 >0.5 >0.5 >0.5 
Neutrophils >0.5 >0.5 >0.5 >0.5 
Lymphocytes >0.5 >0.5 >0.5 >0.5 
Monocytes >0.5 >0.5 >0.5 >0.5 
Eosinophils >0.5 >0.5 >0.5 >0.5 
Basophils >0.5 >0.5 0.043*  >0.5 
1 Mothers given sdNVP at onset of labour n=72 (birth and six wks) 
  Mothers not taking NVP at onset of labour n=12 (birth and six wks) 
2
 Infants exposed to maternal sdNVP n=70 (birth and six wks); no blood counts were 
performed on two of the infants at six wks 
  Infants not exposed to any NVP n=12 (birth and six wks) 
* Increased in the presence of NVP 
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3.4 Discussion 
 
Progressive physiological maturation of the immune system results in age-dependent 
differences in immune function in infants, adolescents and adults (Jaspan et al., 
2006). In Chapter 2, we showed that EU infants produce significantly more IFN-γ at 
birth. In this Chapter we therefore explored whether significant changes in the 
leukocyte counts, particularly lymphocytes, could account for the enhanced IFN-γ 
production of EU infants or whether the short exposure to sdNVP could influence 
leukocyte counts. 
 
The full blood count (FBC) or complete blood count (CBC) automated assay was the 
method of choice over alternative assays like Flow Cytometry (Shahabuddin et 
al.,1998) and direct and indirect immunofluorescence (Solinger,1985) due to the 
method (i) being simple and easy to perform; (ii) did not require the use of expensive 
antibodies; (ii) could be performed on small amounts of blood that did not require 
sophisticated processing and (iv) did not require that the operator undergo an 
intensive training programme. Notably, the FBC provides information about the types 
and numbers of cells in the blood, especially red blood cells, white blood cells and 
platelets. For our purposes, a total WBC cell count was required and the FBC assay 
adequately fulfilled this purpose. Limitations of the method include the fact that the 
blood represents only about 2% of the total lymphocyte pool in the normal adult 
human body and it is therefore not possible to estimate the changes in the number of 
lymphocytes within the lymphoid tissues by using data derived only from blood 
(Westermann et al., 1990).  
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It is important to note that our results came from a cohort of healthy and HIV-1 
infected adult women and their newborn infants of African descent. Aside from 
demonstrating time dependent maturational changes in the control and EU infants as 
well as the leukocyte changes influenced by pregnancy in the mothers (control and 
HIV-1 infected) we could establish reference limits corresponding to “normal values” 
for these groups since earlier data suggests that the leukocyte counts in people of 
African descent are significantly lower than in caucasians (Sadowitz et al., 1983). 
Aside from race differences, it has also been recognized that peripheral blood 
lymphocyte subsets of adults can also vary in accordance to age, and environmental 
factors (Chng et al., 2004). Some of these same factors, including gender, have been 
shown to influence leukocyte counts of infants (Taha et al., 2002; European 
Collaborative Study, 2003; 2004) and children up to eight and 12 years (European 
Collaborative study, 2003) of age. 
  
Using the Act5diff haematology analyzer therefore we demonstrated that amongst 
infants (i) there are no statistically significant differences in the proportions or 
absolute leukocyte types of control and EU infants at birth; (ii) six weeks after birth EU 
infants have significantly different proportions and absolute eosinophil counts only 
compared to control infants; (iii) absolute lymphocyte counts are not significantly 
different either at birth or at 6 weeks between control and EU infants; (iv) while the 
proportion of blood cell types changes over time for both control and EU infants 
(neutrophils and basophil proportions decrease and lymphocyte and eosinophil 
proportions increase significantly with time) this does not hold true for the absolute 
leukocyte counts of EU and control infants (neutrophil, monocyte, eosinophil and 
basophil counts decrease with only lymphocyte counts increasing with time for EU 
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infants and only decreases in neutrophil, monocyte and basophil counts being 
significant for control infants); (v) the predominant cell type (based on absolute 
counts) of infants (control and EU) at birth are neutrophils while at six weeks it is 
lymphocytes and (v) sd NVP increased basophil counts of infants at birth but at six 
weeks the effect was no longer present. For mothers (i) some leukocyte counts at 
delivery compared to the profiles found 6 weeks post partum; (ii) at the time of birth 
HIV-1 positive mothers have reduced eosinophil and basophil absolute levels 
compared to uninfected mothers and (iii) the single dose of NVP taken by the mother 
at the onset of labour does not affect the leukocyte counts significantly. 
 
Neutrophil and basophil proportions decrease in the uninfected control infants during 
the first six weeks of life and lymphocyte counts increase within the first 6 weeks of 
life. The significant increase in the eosinophil population has not been previously 
reported. Interestingly, eosinophilia is a feature of parasitic infections, allergic 
disorders and some drug reactions (Zuo et al., 2007). The significant decrease over 
time of the absolute monocyte count noted in our study may reflect the significant 
changes in cell types characteristic of a maturing immune system i.e. change from 
innate to adaptive immune responses. 
 
During pregnancy physiologic immune adaptations occur involving changes in cell 
counts, phenotypes, functions and soluble factors e.g. cytokines such that a 
successful pregnancy is established and maintained (Luppi, 2003). Thus, the 
changes observed amongst control and HIV-infected mothers from labour to 6 weeks 
post partum were not unexpected. In fact, a study by Thompson et al., (1999) 
suggests that uninfected maternal peripheral blood shows an increase in the total 
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white blood cell count following labour. Variability in the blood counts of the mothers 
are likely to be indicative of inflammatory states produced by disease states e.g viral 
(HIV, as is the case in this study), bacterial (tuberculosis) and other protozoal or 
rickettsial infections. 
 
Lymphocyte counts did not differ significantly between control and EU infants either at 
birth or at 6 weeks, thus by extrapolation the higher IFN-γ levels in EU infants in 
Chapter 2 are unlikely to be the result of differential counts between these two 
groups. Short term antiretrovirals did impact on cell counts in that basophil counts 
were increased at birth but these normalized by six weeks, therefore NVP was 
unlikely to have influenced IFNγ production in the EU infants in such a way that could 
account for differences in production of IFN-γ between control and EU infants. It 
should be noted that all the infants from the cohort in Chapter 2 received NVP so the 
question of NVP effects on IFN-γ production was not addressed directly. 
 
In conclusion, the differences noted in IFN-γ production between control and EU 
infants in early life could not be attributed to altered distributions of the major 
leukocyte groupings. 
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CHAPTER 4 
 
 
Identifying mononuclear cell types that produce IFN-γ in the HIV-1 exposed 
uninfected infant   
 
4.1 Introduction 
 
Early innate production of IFN-γ is a critical step in immunological defence against 
intracellular pathogens (Chougnet et al., 2000; Suen et al., 1998 and Trivedi et al., 
1997), playing a role in determining whether cell mediated or humoral responses will 
predominate. IFN-γ is secreted mainly by T lymphocytes (CD4+ and CD8+) and by NK 
cells, modulating the function of a wide variety of cell types (Trinchieri, 1985) and 
possibly amplifying activation of these same cells in a variety of tissues (Lewis, 1990). 
IFN-γ has dramatic effects on monocyte and macrophage function and is probably the 
most important mediator of macrophage activation (Murray et al., 1998). 
 
The principle that the cytokine environment present at the time of priming influences 
responses and infection outcome also applies in neonates. Impaired immune 
protection of infants has been attributed to the predominant Th2 type responses 
(Marodi, 2006). Furthermore, the production of IFN-γ, a Th1 cytokine, is impaired in 
early life (Wilson et al., 1986), with a lag in the ability to produce IFN-γ occurring for at 
least the first two months of life (Burchett et al., 1998). Over time, both the capacity of 
T cells to produce IFN-γ and the number of memory T cells increases (Sanders et al., 
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1998). IFN-γ is produced in larger amounts by T cells that have been previously 
activated in vivo by their interaction with suitably presented antigens.   
 
In Chapter 2 we established that whole blood cultures of newborn infants exposed in 
utero to HIV-1 produce significantly more IFN-γ than unexposed infants following PHA 
or BCG stimulation. In Chapter 3, we demonstrated that absolute lymphocyte counts 
did not differ significantly between control and EU infants at birth or at six weeks and 
that exposure to NVP administration did not influence the lymphocyte counts at either 
of these time points, suggesting that increased IFN-γ in EU infants was not likely to be 
due to greater numbers of lymphocytes in the cultures of this group. Lymphocytes 
comprise the two major IFN-γ producers, T cells (CD4+ and CD8+) and NK cells, as 
well as B cells. The remaining cell types in whole blood viz. polymorphonuclear 
neutrophils and monocytes are not known to produce IFN-γ when stimulated, 
however monocytes have been reported to have an accessory role in enhancing 
lymphocyte IFN-γ production (Mckenzie et al., 1993; Carson et al., 1995). What is not 
apparent from using whole blood cultures is which cells are contributing towards the 
total amount of IFN-γ secreted. We therefore wanted to establish which mononuclear 
cell types contributed significantly to IFN-γ produced in response to mitogen (PHA) or 
vaccine (BCG), in HIV-1 exposed uninfected infants. This was achieved using a 
whole blood ICC assay which allows the identification of IFN-γ producing cell types. 
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4.2 Materials and methods 
 
4.2.1 Study subjects and samples 
 
Participants used in this part of the study formed part of the HIV Protective Immunity 
and Perinatal Exposure study described in Chapter 3 section 3.2.1. Blood samples 
from eight HIV-1 infected mothers and their 10 week old EU infants were utilized for 
this study. In addition, blood samples from one HIV-1 seropositive mother and her EU 
newborn (DNA PCR-negative at six weeks and 10 weeks) and two controls (HIV-1 
seronegative mothers and their newborn infants) were also included for ICC analysis. 
All HIV-1 infected mothers and their infants received a standard regimen of one dose 
each of NVP (200 mg for the mother and 2 mg/kg for the infant). Two mothers 
received three drugs NVP, AZT and 3TC for approximately four months prior to 
sample collection. 
 
Venous blood was collected in seven millilitre sodium heparin (Na Hep) and five 
millilitre EDTA vacutainer tubes and was processed within three hrs of collection. 
Blood collected in the Na Hep tubes was used for ICC determination and EDTA blood 
tubes were used for DNA PCR or viral load and CD4+ T cell count determinations. 
Blood from the one EU birth sample was drawn within 48 hrs of birth after being given 
a dose of NVP. Bloods from the eight EU infants were drawn 10 weeks after they had 
received NVP. For infants, HIV-1 DNA PCR tests were carried out to establish 
infection status and timing of infection using the Roche Amplicor HIV-1 DNA PCR 
assay version 1.5 (Roche Diagnostic Systems, Inc, New Jersey, USA).Maternal viral 
loads were measured from plasma using the Roche Amplicor RNA Monitor assay 
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(Roche Diagnostic Systems, Inc, New Jersey, USA) with a lower detection limit of 400 
RNA copies/ml. Maternal CD4+ T cell counts were determined using the commercially 
available FACSCount system (Becton Dickinson, San Jose, CA).  
 
4.2.2 Intracellular cytokine assay 
 
Blood samples collected in NaHep tubes were used for ICC analyses. Whole blood 
(200 µl) was either stimulated with PHA (final concentration 5 µg/ml) or BCG vaccine 
(final concentration 15 µg/ml) or unstimulated (samples were incubated with 4 µl of a 
1:10 dilution of dimethylsulphoxide (DMSO)(Sigma-Aldrich Corp., St Louis, MI, USA). 
2 µl of the co-stimulatory antibodies CD28 and CD49d (BD Biosciences, San Jose, 
CA, USA), diluted 1:10 in sterile phosphate buffered saline (PBS) (NICD media 
department, Sandringham, SA) as well as 4 µl of the secretory inhibitor Brefeldin A 
(BFA) (Sigma-Aldrich Corp., St Louis, MI, USA ) were added to each sample. 
Samples were incubated for 12 hrs at 37°C, after which they were cooled to 18°C. To 
arrest further stimulation and to remove cells from the sides of the sample tubes 20 µl 
of EDTA (final concentration 20 mM)( (Roche Diagnostic Systems, Inc, New Jersey, 
USA) was added to each sample. Samples were mixed vigorously on a vortex and 
incubated for 15 minutes at room temperature. Thereafter, 2 ml 1x FACS lysing 
solution (BD Biosciences, San Jose, CA, USA) was added to each tube and 
incubated for 10 minutes at room temperature in order to simultaneously lyse the 
erythrocytes and fix the leukocytes. The samples were then centrifuged at 2000 rpm 
for five minutes at room temperature and the supernatants decanted. Next, cells were 
permealized by adding 500 µl of FACSperm (BD Biosciences, San Jose, CA, USA) 
(diluted 1:10 in distilled water) and incubated for 10 minutes. at room temperature. 
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The cells were then washed twice with wash buffer (NICD media department, 
Sandringham SA). Three and four colour staining using antibodies for surface and for 
intracellular IFN-γ was carried out and distinguished NK cells (CD16+CD56+CD8-
CD3+), CD4+ T cells (CD3+CD4+), CD8+ T cells (CD3+CD8+), monocytes (CD14+) and 
B cells (CD19+). The antibody combinations used are listed in Table 4.1. Samples, to 
which the relevant antibodies were added, were covered with foil, placed in a dark 
cupboard and subsequently incubated for one hour at room temperature then washed 
and resuspended in 150 µl of PBS containing 1% paraformaldehyde (Electron 
Microscopy Sciences, Pretoria, South Africa). Samples were stored at 4°C until 
acquisition on a Flow Cytometer (described in section 4.2.2.5). Samples were 
acquired within 24 hrs.  
 
Table 4.1 Fluorescent antibody combinations used for staining whole blood 
samples 
Tube number FITC PE PERCP APC 
1 CD16+CD56+ IFN-γ CD8+ CD3+ 
2  IFN-γ CD4+ CD3+ 
3 CD14+ IFN-γ CD19+  
NK cells: C16+CD56+CD8-CD3- 
CD4+ T- cells: CD3+CD4+ 
CD8+ T cells: CD3+CD8+ 
Monocytes: CD14+ 
B cells: CD19+ 
 
 
4.2.3 Flow Cytometry 
 
All samples were acquired on a Becton Dickinson FACScalibur Flow Cytometer 
(Becton Dickinson Immunocytometry Systems, San Jose CA). BD Calibrite beads and 
BD FACSComp software version 6.3.2 (Becton Dickinson Immunocytometry 
Systems, San Jose CA) were used for assessing instrument performance before use. 
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Samples stained with a single fluorescent antibody were set up with each experiment 
and served as the compensation tubes. Cell populations were gated based on their 
forward scatter (FSC) and side scatter (SSC) properties, that is, cells were 
distinguished on the basis of size and granularity, respectively. Fig. 4.1 - 4.3 provides 
an example of the gating strategy used in this study. At least 20 000 cells were 
collected during acquisition. Data was analysed using Flowjo software (Tree Star, 
San Carlos, CA, USA) and results were expressed as the percentage of IFN-γ 
producing cells expressing specific cell type markers that identify CD4+ and CD8+ T 
lymphocytes, NK cells, monocytes and B cells. A positive response was considered 
as ≥0.1% IFN-γ producing cells after subtracting the background staining from cells 
stimulated with anti-CD28 and anti-CD49d in the absence of PHA and BCG. 
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4.3 Statistical analyses 
 
The Wilcoxon signed rank test was used to determine whether there were any 
significant differences in IFN-γ production between the different cell types and to 
establish if cell type specific production of IFN-γ differed for the different stimuli.  
Statistical analyses were performed using SPSS software (version 11.0, SPSS Inc., 
Chicago, IL). All statistical tests were two-tailed and considered significant at P<0.05.  
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4.4 Results 
 
4.4.1 Samples for ICC analysis 
 
Since IFN-γ production is poor in newborns, we selected to address the question of 
which cell types were more likely to produce IFN-γ in infants at 10 weeks of age, a 
time when their immune capability is much improved. We therefore focused this 
analysis on eight 10 week old EU infants (DNA PCR negative at six weeks and 10 
weeks) and their HIV-1 infected mothers. It was interesting to include mothers in the 
ICC analyses to see how their IFN-γ producing capacity compared to their infants. We 
also included two HIV-1 negative mothers and their newborn infants and one HIV-1 
seropositive mother and her newborn EU infant. Table 4.2 shows the characteristics 
for the mother-infant pairs used for this study.  
 
Table 4.2 Characteristics of mothers and infants 
 
Infant blood 
taken after NVP 
Mother-Infant 
ID* 
Infant age 
at time of ICC 
Maternal CD4+ 
(cells/µl) 
Maternal viral 
load (RNA 
copies/ml) 
 UNINFECTED CONTROLS (MOTHERS AND INFANTS)  
  473 Birth 1473 ND 
  481 Birth ND ND 
HIV-1 INFECTED MOTHERS AND THEIR EU INFANTS 
NVP yes 429 Birth 939 488 
NVP yes 667 10 wks 709 845 
NVP+AZT+3TC+ yes 670 10 wks 197 <400 
NVP yes 683 10wks 1033 <400 
NVP yes 685 10 wks 525 217 000 
NVP yes 742 10 wks 463 5 840 
NVP yes 743 10 wks ND 4 180 
NVP+AZT+3TC+ yes 777 10 wks 191 <400 
NVP yes 778 10 wks 509 40 600 
ND: not determined  
* Samples were coded as the ID number shown preceded with an “M” for mother and a “C” for her matched child 
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4.4.2 IFN-γ production by different cell types in 10 week old EU infants  
 
In order to determine which cells are the main producers of IFN-γ in EU infants, ICC 
analysis and Flow Cytometry was carried out on whole blood collected from eight 10 
week-old EU infants. The percentage of CD4+ and CD8+ T cells, NK, CD14+ and 
CD19+ cells producing IFN-γ were compared for blood that was unstimulated (Fig. 
4.4A) or stimulated with PHA (Fig. 4.4B) or BCG (Fig. 4.4C). Results were obtained 
for CD19+ cells for only four of the eight infants. Notably, there are significant 
differences in the ability of different cell types to produce IFN-γ (Fig. 4.4 A, B and C). 
A significantly higher percentage of NK cells produced IFN-γ compared to CD4+, 
CD8+ and CD14+ cells (P=0.012), irrespective of the stimulus. Although there was a 
trend towards reduced IFN-γ production in B cells (CD19+) compared to NK cells and 
an increase relative to other cell types, this was not significant. No appreciable 
differences could be noted in the percentages of CD4+, CD8+ and CD14+ cells 
(monocytes) involved in IFN-γ production. 
We next questioned the extent to which IFN-γ could be induced by the two stimuli 
(PHA and BCG). Significant differences in the production of IFN-γ, between the 
different stimuli, for each of the cells are listed in Table 4.3. In general, PHA proved to 
be a more potent stimulus than BCG, although increases in IFN-γ production were 
mostly marginal. PHA significantly increased the proportions of IFN-γ-producing NK 
cells (P=0.05), proportions of CD4+ (P=0.012) and CD8+ (P=0.042) T cells when 
compared to unstimulated control cells. There were no significant differences in cell 
 71
type specific IFN-γ production for any other comparisons (PHA vs unstimulated, BCG 
vs unstimulated, or PHA vs BCG).  
 
Table 4.3 Ability of cell types to produce IFN-γ in response to different stimuli. 
Significant differences are presented  
Cell type PHA vs 
Unstimulated 
BCG vs 
Unstimulated 
PHA vs BCG 
CD4+ T cells 0.012* >0.05 >0.05 
CD8+ T cells 0.042* >0.05 >0.05 
CD56+ CD16+ (NK 
cells) 
0.050* >0.05 >0.05 
CD19 (B cells) >0.05 >0.05 >0.05 
CD14 
(monocytes) 
>0.05 >0.05 >0.05 
* increased with PHA stimulation   
 
Fig. 4.5 shows the data for each individual infant in order to illustrate the relative 
changes in IFN-γ production between cell types when exposed to different stimuli. 
The magnitude of IFN-γ responses was quite variable between different individuals, 
but patterns of responses were similar for some. For example infants C670, C777, 
C778, C685 and C683 in general had similar response profiles when stimulated with 
PHA or BCG. However, the remaining three infants were either poorly or non-
responsive to one or other stimulus (C667, C742 and C743). 
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Fig. 4.5 IFN-γ production by different cell types of 8 individual EU infants (C670, 
C777 etc) at 10 weeks 
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4.4.3 IFN-γ production in mothers of EU infants 
 
The distribution of cells, in peripheral blood, contributing to IFN-γ production in HIV-1 
infected adults is influenced by stage of HIV-1 disease progression (Lieberman et al., 
2001). Overall, the immune integrity of all the mothers was considered to be good as 
viral loads were almost undetectable (<400 copies/ml) with one mother having a viral 
load of 217 000 copies/ml (Table 4.2). Mothers with the higher viral loads had CD4+ T 
cell counts greater than 400 cells/µl. Intriguingly, two mothers had low viral loads 
(<400 copies /ml), yet low CD4+ T cell counts (<200 cells/µl). Fig. 4.6 shows the ICC 
assay data obtained for each HIV-1 infected mother, illustrating the relative abilities of 
the cell types to produce IFN-γ. Results were obtained for CD19 cells for only four of 
the eight mothers. Fig. 4.7. shows a comparison of IFN-γ production by CD4+ and 
CD8+ T cells, NK cells and CD14+ cells in response to PHA (PHA in general being the 
more potent stimulus), for EU infants and their infected mothers. Not unexpectedly all 
four cell types from HIV-1 infected mothers produced substantially more IFN-γ than 
their infants. Interestingly, amongst the HIV-1 infected mothers, CD8+ T cells were the 
better producers of IFN-γ however, in the EU infants the NK cells produced most of 
the IFN-γ. 
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 76
MONOCYTESNKCD8CD4
%
 
IF
N
-
γ
PR
OD
UC
TI
O
N
10
8
6
4
2
0
n= 8 8 8 8
CELL TYPE
CELL TYPE
8888
40
30
20
10
0
MONOCYTESNKCD8CD4
A
B
INFANTS
MOTHERS
%
 
IF
N
-
γ
PR
O
D
UC
TI
O
N
P=0.012
P=0.012
P=0.012
P=0.017
P=0.012
P=0.012
P=0.017 P=0.012
P=0.012
P=0.012
%
 
IF
N
-
γ
PR
OD
UC
TI
O
N
%
 
IF
N
-
γ
PR
O
D
UC
TI
O
N
Fig. 4.7 IFN-γ production by PHA stimulated cells of EU infants at 10 weeks 
and their HIV-1 infected mothers 
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4.4.4 IFN-γ production at birth 
 
Having shown that NK cells were the major cell type producing IFN-γ in infants at 10 
weeks of age we wanted to determine whether there were any differences in the 
production of IFN-γ in newborns. ICC analysis was thus conducted on two control 
uninfected infants and their corresponding HIV-uninfected mothers, and one EU 
newborn and its corresponding mother (Fig. 4.8). As demonstrated earlier, NK cells 
proved again to be the major producers of IFN-γ in the control HIV-1 negative infants, 
followed by prominent IFN-γ production by B cells (Fig. 4.8 A and B). In the one EU 
newborn infant, responses by all of the cell types, with the exception of CD4+ T cells, 
were largely undetectable (Fig. 4.8 C). It was interesting that all mothers of newborns 
(uninfected and HIV-1 infected) had in particular poor CD8+ T cell production of IFN-γ, 
in contrast to that found amongst HIV-1 infected mothers tested at 10 weeks (Fig. 
4.7), likely reflecting the altered immunological milieu associated with pregnancy.  
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Fig. 4.8 IFN-γ production by the different cell types of infants at birth and their 
corresponding mothers. (A and B) control uninfected infants at birth (C473, C481) 
and their uninfected mothers (M473, M481) and (C) EU infant at birth (C429) and 
its HIV-1 infected mother (M429) 
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4.5 Discussion 
 
Newborn infants are highly susceptible to infections and deficiencies in their immune 
system (innate and adaptive) have been thought to account for the failure of infants to 
mount protective responses against pathogens (Delespesse et al., 1998). IFN-γ 
production, which is impaired in newborns (Wilson et al., 1986) is critical for the 
development of effective immune responses and is secreted by T cells and NK cells 
under appropriate stimuli during the immune response (Szabo et al., 2003).  Since we 
had established, in Chapters 2 and 3, that EU infants produce significantly more IFN-γ 
than control infants and that the increased production was not due to increased 
lymphocyte counts in these infants, we wanted to determine which mononuclear cell 
types contributed to the IFN-γ produced in response to mitogen (PHA) or vaccine 
(BCG).  
 
The ability to measure cytokine production at a cellular level using ICC staining and 
Flow Cytometry has proved to be a very powerful tool because (i) a given cell 
population can be analyzed since parameters such as size and granularity, as well as 
expression of surface and intracellular markers defined by fluorescent antibodies can 
be used for the separation, (ii) this approach permits the detection of functional 
populations that respond to specific soluble antigens, (iii) whole blood can be used 
without the need for the separation of specific cell populations – this is an important 
advantage when working with small sample volumes from infants, and (iv) the whole 
blood ICC assay allows the study of individual cells directly ex vivo minimizing 
artifacts due to long term culture. 
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In this study, we demonstrated that: (i) the NK cells of 10 week old EU infants 
produced significantly more IFN-γ than the T cells or B cells, (ii) induced IFN-γ 
responses were undetectable in the one exposed uninfected newborn examined at 
birth, however, in control birth infants NK cells remained the main producers of IFN-γ, 
(iii) maternal CD4+ and CD8+ T cells as well as the NK cells produced substantially 
more IFN-γ with the CD8+ T cells producing the most. 
 
Excessive IFN-γ production at the maternal-foetal interface has been shown to be 
deleterious to the placental integrity as well as being a major cause of foetal loss 
(Wegmann et al., 1993). The bias of foetal immunity to Th2 polarization therefore 
serves to protect against Th1 placental and foetal damage but plays a significant role 
in ‘damping’ the newborns innate immune responses. Since infants have a Th2 driven 
immune system plus the fact that they are essentially antigen-inexperienced and have 
virtually no development of specific/adaptive immunity it was not surprising that the 
NK cells were found to be the dominant IFN-γ producers. IFN-γ production by NK 
cells has been reported to play a central role in immunity, being the main cytokine 
produced by NK cells early in the immune response, and driving subsequent Th1 
responses (Trinchieri, 1995). CD4+ and CD8+ T cells and NK cells of HIV-1 infected 
mothers, on the other hand, produced substantially more IFN-γ than their infants, with 
the CD8+ T cells proving to be better producers of IFN-γ in the HIV-1 infected 
mothers. In contrast all mothers of newborns (uninfected and HIV-1 infected) had 
poor CD8+ T cell production. This result may be explained by the fact that chronically 
HIV-1 infected mothers have expansions of CD8+ T cells as a result of their infection 
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when compared to the uninfected adults where there is no such priming of cells, and 
that the immunological environment differs in HIV-1 infected mothers at delivery 
compared to 10 weeks later. 
 
Importantly findings in infants have shown that the infant immune system is unique 
from that of the adult and that the innate immune response predominates in newborns 
and also by 10 weeks of age. This is particularly interesting when looking at the 
responses to BCG vaccine given at birth, as the response then measured at 10 
weeks would be expected to be largely attributed by a memory CD4+ T cell response. 
However, it was apparent that higher proportions of NK cells produce IFN-γ even 
when “unstimulated” (note these are not strictly unstimulated as the ICC assay control 
includes addition of CD49d and CD28 antibodies used to enhance responsiveness to 
a second stimulus of the test samples) in both uninfected controls (at birth) and EU 
infants (10 weeks), it is therefore very likely that the increased secreted levels of IFN-
γ reported in six week old infants in whole blood cultures following BCG vaccination 
(Chapter 2) would be due to production of both innate (particularly NK cells) and/or 
acquired immune responses (CD4+ and/or CD8+ T cells). 
 
Given the variation in IFN-γ response profiles obtained for the eight EU infants, it is 
likely this same extent of variation would be encountered in birth samples. Therefore, 
it would be important to increase the sample size for study of these responses at birth 
(control and EU infants) as the data shown in the small numbers here cannot be 
considered as representative. In Chapter 2 it was established that 48% of newborns 
had detectable levels of IFN-γ induced at birth in response to BCG, a response 
suggested to be non-specific in nature. However by ICC assay one control newborn 
 82
showed a CD4+ and CD8+ T cell response to BCG, and the one EU newborn had a 
positive CD4+ T cell response to BCG, suggesting that memory T cell responses to 
BCG are present in some infants at birth. Whether these can be explained by 
maternal exposure to BCG, Mycobacterium tuberculosis or some other cross-reacting 
mycobacterium, needs to be established in future studies. 
 
Innate immunity as the first line of defence against invading pathogens viz. bacterial 
and viral infections, is particularly important in warding off infections in the newborn 
infant and permits the development of the adaptive immune response over time. 
Numerous studies have however shown that under certain conditions, newborns are 
able to mount adult-like protective T cell responses (Legrand et al., 2006; Marchand 
et al., 2003). The ability of infants to induce strong lymphoproliferative responses and 
Th1 type cytokine responses is important as this impacts on the induction of 
protective immune responses by vaccines. It is recognized that immunological 
responses are governed by factors such as dose and route of vaccine administration 
(Goetch et al., 2000). For the development of more effective infant vaccines it is 
important therefore to identify the immune system deficiencies and how they 
contribute to the increased vulnerability seen in infants. Furthermore, immune 
dysregulation at an early age in the EU infant may through exposure to maternal HIV-
1 influence the development of subsequent innate and adaptive immune responses to 
HIV-1 itself, other organisms and vaccines.   
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CHAPTER 5 
 
 
Concluding remarks  
 
Deficiencies of both innate and adaptive immunity contribute to the impaired neonatal 
host defence making infants more susceptible to infectious diseases. Immaturity of T 
cell immunity and thus difficulty in priming neonatal T cells and a bias to T helper 
type-2 responses are considered to be obstacles to inducing protective immune 
responses by vaccines in neonates.  
 
The environment present at the time of immune cell priming influences the resulting 
response and therefore the outcome of infection. Interestingly, studies have shown 
that the Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine given at birth 
induces potent Th1-type immune responses and this influences the immune response 
to unrelated antigens in early life (Marchand et al., 1999; Ota et al., 2002). Low-dose 
exposures to HIV-1 have also been associated with the development of T helper type-
1 responses (Shearer and Clerici, 1996) and there is substantial evidence showing 
immune consequences of exposure to maternal HIV-1 (or by virtue of being born to 
an HIV-1 seropositive mother) in HIV-1 exposed infants (see examples of HIV-1 
specific responses and innate immune responses in sections 1.7.1 and 1.7.2, 
respectively). Adding further to this growing list of altered immune features of the EU 
infant, findings from this study showed an enhanced capacity to produce IFN-γ among 
EU newborns of HIV-1 infected mothers. In addition, EU infants also showed different 
profiles of maturation when stimulated with PHA or BCG (over the first 6 weeks of 
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life), further distinguishing them from their uninfected counterparts.  Findings revealed 
that IFN-γ produced in response to BCG, studied as a vaccine response (given at 
birth that is measured at 6-10 weeks of age), is in fact predominantly produced by 
innate immune cells (particularly NK cells) and comparatively only very small 
proportions of T cells produced IFN-γ (considered as part of an adaptive immune 
response or recall response). That 48% of newborns among EU infants already had 
demonstrable responses to BCG (prior to BCG vaccination) suggests that this is 
either non-specific in nature (i.e. innate immune cells such as NK cells are stimulated) 
or may involve T cell responses (as suggested by ICC data in Chapter 4) developed 
due to prior exposure in utero to mycobacterial organisms that may cross-react with 
BCG, or what seems unlikely, to BCG itself. Further studies are required to establish 
the true nature of the origin and specificity of these responses.  
 
An important question that remains is how the altered immune environment of EU 
infants, because of earlier antigenic exposure than would occur in uninfected infants 
born to HIV-1 uninfected mothers, impacts on immune responses to other organisms 
and vaccines. Certainly, the development of HIV-1 specific responses in EU infants 
has been associated with protective immunity to HIV-1. It may be seen to be 
advantageous to an infant to have a “fast-tracked” immune development through 
greater antigenic exposure in early life. However, it is also likely that other aspects of 
early immune development may be compromised through having an HIV-1 infected 
mother, whose immune system and nutritional well-being is impaired to varying 
extents dependent on stage of disease. With lower maternal CD4+ T cell counts, 
mothers would also become susceptible to secondary infections which then would 
also expose the child to a greater number of infections than would occur with a more 
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robust healthy immune system. Other factors like poor passive transfer of maternal 
antibodies in such women could also be another factor contributing to infant 
susceptibility to certain organisms. 
 
It remains important in the future to conduct studies on immune response capability 
as described here for IFN-γ, but at the same time to follow-up these infants and 
monitor their immune responses to important childhood vaccines, and to assess their 
susceptibility to other infections in relation to immune response capacity (using clearly 
defined immune parameters of innate and adaptive immune responses). It will be 
comparisons such as these that will help us to understand if some of these altered 
immune responses are advantageous or disadvantageous to the developing infant, 
and whether susceptibility to other infections in the EU infant may be a consequence 
of their own immune inability to deal with an infectious event, maternal factors or due 
to the fact that their environmental exposure to infectious organisms is heightened. 
 
Understanding the cytokine environment, dose and nature of the antigen as well as 
other neonatal immunological characteristics may contribute to developing more 
effective vaccination strategies.  The EU infant represents an important model for 
studying not only the consequences of early antigenic exposure in infants, but also 
provides a very important model for the study of correlates of protective immunity to 
HIV-1, as these infants have escaped acquiring HIV-1 infection despite exposure to 
maternal HIV-1.  
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APPENDIX A: Abbreviations 
 
 
ADCC     antibody-dependant cellular cytotoxicity 
AIDS      acquired immune deficiency syndrome 
APC      antigen presenting cells  
ART      antiretroviral therapy 
ARV      antiretrovirals 
AZT      Azido-Thymidine, zidovudine  
BCG      Bacillus Calmette-Guérin 
BFA      brefeldin A  
BSA      bovine serum albumen 
CBC      complete blood count  
CD4+      T lymphocyte 
CD8+      T lymphocyte 
CD14+    monocytes 
CD16+ CD56+   NK cells 
CD19+    B cells 
CD80      The protein CD80 is a molecule which provides 
                                                      a costimulatory signal necessary for T  
                                                      cell activation 
CD86      The protein CD86 is a molecule which provides 
                                                      a costimulatory signal necessary for T  
                                                      cell activation 
CD40      A receptor molecule on the surface of mature B 
                                                      cells 
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CD45RA+    naïve antigen expression in T-lineage neoplasm 
CD45RO+    mature antigen expression in T-lineage neoplasm 
CFU      colony forming unit 
CHBH     Chris Hani Baragwanath Hospital 
C5a      complement 5a 
CMI      cell mediated immunity 
CTLs      cytotoxic T lymphocytes  
CWCH    Coronation Women and Childrens hospital 
DNA      deoxyribose nucleic acid  
DMSO    dimethylsulphoxide 
EDTA      ethylenediamine tetra-acetic acid 
EU      exposed uninfected 
ELISA     enzyme linked immunosorbent assay 
ELISPOT    enzyme linked immunospot assay 
FcR11    low affinity receptors  
FSC      forward scatter 
HIV      human immunodeficiency virus 
HSC      haematopoetic stem cells  
hrs      hours 
ICC      intracellular cytokine staining 
IgA      immunoglobulin A 
IgG      immunoglobulin G 
IgM      immunoglobulin M 
IgE      immunoglobulin E 
IL-1      interleukin-1 
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IL-6      interleukin-6 
IL-8      interleukin-8 
IL-12      interleulin-12 
IL-18      interleukin-18 
IFN-α      interferon-alpha  
IFN-β      interferon-beta  
IFN-γ      interferon-gamma 
IQR      interquartile range 
LPS      lipopolysaccharide 
ml      millilitre 
MHC      major histocompatibility complex  
NK      natural killer cells  
NADPH    nicotinamide adenine dinucleotide phosphate  
Na Hep    sodium heparin 
NICD      National Institute for Communicable Diseases 
PBMC     peripheral blood mononuclear cells  
PBS      phosphate buffered saline 
PCR      polymerase chain reaction 
PHA      phytohaemagglutinin 
PRRs      pattern recognition receptors  
PIPE      protective immunity and perinatal exposure study 
pg      picogram 
PMTCT    perinatal mother to child transmission  
RNA      ribose nucleic acid  
rpm      revolutions per minute 
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SSC      side scatter 
sdNVP    single dose nevirapine 
TB      tuberculosis 
Th1      T helper-type 1 
Th2      T helper-type 2 
TCR      T cell receptor 
TLRs      toll-like receptors 
TI      thymus independent  
TNF-α     tumour necrosis factor alpha 
TGF-β    transforming growth factor 
3TC      Lamivudine (2',3'-dideoxy-3'-thiacytidine) 
µg      microgram 
µl      microlitre 
µM      micromolar 
week(s)    week(s) 
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APPENDIX B: Composition of buffers and media 
 
 
Haematology diluent (wash buffer) 
Dissolve NaCl   8.12 g in 200 ml distilled water 
   KCl   0.28 g in 100 ml distilled water 
   KH2PO4  0.26 g in 100 ml distilled water 
   LiCl   0.43 g in 200 ml distilled water 
Combine and make up to 1 litre with distilled water 
Add EDTA (0.36 g) and adjust pH to 7.2 with HCl 
 
Fixer 
1.5% Formaldehyde PBS, 2% BSA 
 
Phosphate Buffered Saline (PBS) 
   NaCl   80.0 g 
   NA2HPO  11.6 g  
   KH2PO4  2.0 g 
   KCl   2.0 g 
Combine and make up to 1 litre with distilled water 
Adjust pH to 7.0 
 
Wash Buffer for ELISA 
Add 0.05% Tween-20 to PBS buffer 
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APPENDIX C: List of Suppliers 
 
Item        Manufacturer 
 
Plasticware  
Falcon polypropylene tubes   Becton Dickinson, San Jose, CA 
Sterile pipettes     Adcock Ingram scientific South Africa 
Micro-centrifuge tubes, 1.5 ml   Eppendorf, Hamburg, Germany 
96-well flat bottomed plates   Nunc A/S, Roskilde, Denmark 
96 well microtitre plate round bottom  Corning, Costar Corp., Cambridge 
96 well microwell plates Falcon   Becton Dickinson, San Jose, CA 
3.6 ml storage vials     Nunc A/S, Roskilde, Denmark 
 
ICC Antibodies 
FITC-conjugated mouse anti-human CD16 Becton Dickinson, San Jose, CA 
FITC-conjugated mouse anti-human CD56 Becton Dickinson, San Jose, CA  
FITC-conjugated mouse anti-human CD14 Becton Dickinson, San Jose, CA  
PerCP CD8      Becton Dickinson, San Jose, CA  
PerCP CD19      Becton Dickinson, San Jose, CA 
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Cytokines 
IFN-γ        R and D systems, Oxon, England 
 
Stimuli 
PHA        Sigma Aldrich, St Louis, MO, USA 
BCG        Statens Serum Institut, Denmark 
 
Cell Culture Media 
RPMI 1640       Sigma Aldrich, St Louis, MO, USA 
Foetal Calf Serum     Adcock Ingram Scientific, South Africa 
 
Chemicals 
Bovine Serum albumin    Sigma-Aldrich, St Louis, MO, USA 
Sodium Hydroxide     BDH, Poole, England 
EDTA        Merck, Darmstadt, Germany ll 
Hydrochloric Acid     Sigma-Aldrich, St Louis, MO, USA 
Potassium Phosphate (KH2PO4   Merck, Darmstadt, Germany 
Potassium chloride (KCl)    Merck, Darmstadt, Germany 
Sodium Chloride (NaCl)    Merck, Darmstadt, Germany 
Sodium Phosphate (NA2HPO)   Merck, Darmstadt, Germany 
 
Blood collection vacutainers 
EDTA vacutainers     Becton Dickinson, San Jose, CA  
Na Heparin vacutainers    Becton Dickinson, San Jose, CA 
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Reagents 
IFN-γ ELISA kit     BD Biosciences Pharmingen San 
                                                                           
Diego California 
 
Reference blood controls    Beckman Coulter Inc. Fullerton CA 
 
Brefeldin A      Sigma-Aldrich St Louis, MO, USA 
Histopaque Ficoll     Sigma-Aldrich, St Louis, MO, USA 
Tween-20      Adcock Ingram Scientific, South Africa 
FACS lysing Solution    Becton Dickinson, San Jose, CA 
FACSperm solution     Becton Dickinson, San Jose, CA 
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APPENDIX D: Statistical evaluation of results 
 
 
SPSS version 11.0 (SPSS Inc. Chicago, III, USA) was used in performing all the 
statistical analyses of the results obtained. All the statistical tests were two-tailed and 
considered significant at P<0.05  
  
Comparison of two samples (Mann-whitney U-test) 
 
The Mann-Whitney U-test is a non-parametric method which usually is used to 
compare medians of non-normal distributions. In this study the unpaired test (Mann-
Whitney U-test) was used, which determines whether two medians differ. The Mann-
Whitney U-test is used when data from two independent samples, possibly of different 
size are being compared. 
 
Wilcoxin signed rank test 
 
The Wilcoxin signed rank test is a non-parametric method that looks for differences 
between two related samples. In this study the Wilcoxin signed rank test was used to 
establish if cell type specific production of IFN-γ differed for the different stimuli. 
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APPENDIX E: Computer software packages 
 
 
This dissertation was produced on Microsoft Word for Windows XP. 
The references were created by Endnote version 9. 
The databases were managed using Microsoft Office Excel 2003. 
Statistical evaluation of results was performed using SPSS version 11.0. 
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APPENDIX F: Ethical clearance 
 
 
This study was approved by the university of the Witwatersrand committee for 
Research on Human Subjects (Medical), protocol number…M071161………………… 
Patients were recruited after informed consent was obtained and the confidentiality of 
all records ensured. 
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